Kinases	Phosphatases	Growth factors	Cytokines	Transcription factors

Fgfr1	Acpp	Clec11a	Il10	Gata6

Pdk4	Dusp23	Gas6	Pf4	Lass4

Srms	Nt5e	Gdf6	Thpo	Lhx4

Srk3	Pon1	Igf1	Wnt5a	Nfatc2

	Ppap2b	Igf2		Per2

		Inhbe		Tal1

		Mst1		Tcf7l2

				Sox9

Kinases	Phosphatases	Growth factors	Cytokines	Transcription factors

Srk3	Pon1	Igf1	Wnt5a	Nfatc2

	Ppap2b	Igf2		Per2

		Inhbe		Tal1

		Mst1		Tcf7l2

				Sox9


Gene ID	I_CN	I_0	Annotation

Kinase

 Unigene43155_xckb	D_U	F_F	Proline-rich receptor-like protein kinase PERK2

 Unigene66089_xckb	U_D	F_F	G-type lectin S-receptor-like serine/threonine-protein kinase SD1-13

 Unigene13595_xckb	U_D	F_F	Protein kinase domain containing protein

 CL3347.Contig1_xckb	U_D	F_F	Cysteine-rich receptor-like protein kinase 8

 Unigene60834_xckb	U_D	F_F	Probable LRR receptor-like serine/threonine-protein kinase At4g29180

 Unigene68690_xckb	U_D	F_F	Proline-rich receptor-like protein kinase PERK10

 Unigene35121_xckb	U_D	F_F	Proline-rich receptor-like protein kinase PERK2

TF

 Unigene65053_xckb	U_D	F_F	MADS-box transcription factor 15

 Unigene34602_xckb	U_F	F_F	Ethylene-responsive transcription factor ABI4

 Unigene69673_xckb	U_F	F_F	Ethylene-responsive transcription factor ERF109

Resistance

 Unigene68271_xckb	U_D	F_F	Leucine-rich repeat extensin-like protein 3

 CL2708.Contig2_xckb	U_D	F_F	Pollen-specific leucine-rich repeat extensin-like protein 1

 Unigene72805_xckb	U_D	F_F	Resistance protein RGA2

 CL6805.Contig1_xckb	F_U	F_F	Hydroxyproline-rich glycoprotein gp1

 Unigene48841_xckb	F_U	F_F	Hydroxyproline-rich glycoprotein gp1

 Unigene46836_xckb	U_D	F_F	Hydroxyproline-rich glycoprotein gp1

 Unigene72060_xckb	U_D	F_F	Hydroxyproline-rich glycoprotein gp1

Gene ID	I_CN	I_0	Annotation

Kinase

			Proline-rich recepto

Gene ID	I_CN	I_0	Annotation

Unigene43155_xckb	D_U	F_F	r-like protein kinase PERK2

Unigene66089_xckb	U_D	F_F	G-type lectin S-receptor-like serine/threonine-protein kinase SD1-13

Unigene13595_xckb	U_D	F_F	Protein kinase domain containing protein

CL3347.Contig1_xckb	U_D	F_F	Cysteine-rich receptor-like protein kinase 8

Unigene60834_xckb	U_D	F_F	Probable LRR receptor-like serine/threonine-protein kinase At4g29180

Unigene68690_xckb	U_D	F_F	Proline-rich receptor-like protein kinase PERK10

Unigene35121_xckb	U_D	F_F	Proline-rich receptor-like protein kinase PERK2

TF

Unigene65053_xckb	U_D	F_F	MADS-box transcription factor 15

Unigene34602_xckb	U_F	F_F	Ethylene-responsive transcription factor ABI4

Unigene69673_xckb	U_F	F_F	Ethylene-responsive transcription factor ERF109

Resistance

Unigene68271_xckb	U_D	F_F	Leucine-rich repeat extensin-like protein 3

CL2708.Contig2_xckb	U_D	F_F	Pollen-specific leucine-rich repeat extensin-like protein 1

Unigene72805_xckb	U_D	F_F	Resistance protein RGA2

CL6805.Contig1_xckb	F_U	F_F	Hydroxyproline-rich glycoprotein gp1

Unigene48841_xckb	F_U	F_F	Hydroxyproline-rich glycoprotein gp1

Unigene46836_xckb	U_D	F_F	Hydroxyproline-rich glycoprotein gp1

Unigene72060_xckb	U_D	F_F	Hydroxyproline-rich glycoprotein gp1


Diagnosis	Cases

Head injury	7

Skin lesions	5

Poisoning	4

Polytrauma	3

Others	2

Diagnosis	Cases

kin lesions	5

Poisoning	4

Polytrauma	3

Others	2


Kind of complications	n = 20 (23.2 %)	Need for reoperation n = 19 (22.0 %)	Way the complication was handled

- Femoral shaft fracture	4 (4.6 %)	4 (4.6 %)	cerclage, cemented stem

- Calcar fracture	1 (1.2 %)	1 (1.2 %)	change of approach

- Dislocation	2 (2.3 %)	2 (2.3 %)	closed reduction

- Sintering	1 (1.2 %)	1 (1.2 %)	larger neck size

- Periprosthetic fracture	6 (6.9 %)	6 (6.9 %)	plate osteosynthesis, cerclage, cemented stem, augmentation, total exchange

- Cup displacement	1 (1.2 %)	1 (1.2 %)	cemented cup

- Infection	2 (2.3 %)	2 (2.3 %)	exchange of head & inlay

- Hematoma	3 (3.5 %)	2 (2.3 %)	lavage, punction

- Thrombosis (%)	0 (0.0 %)	0 (0.0 %)	-

- Pulmonary embolism (%)	0 (0.0 %)	0 (0.0 %)	-

Kind of complications	n = 20 (23.2 %)	Need for reoperation n = 19 (22.0 %)	Way the complication was handled

- Femoral shaft fracture	4 (4.6 %)	4 (4.6 %)	cerclage, cemented stem

- Calcar fracture	1 (1.2 %)	1 (1.2 %)	change of approach

- Dislocation	2 (2.3 %)	2 (2.3 %)	closed reduction

- Sintering	1 (1.2 %)	1 (1.2 %)	larger neck size

- Periprosthetic fracture	6 (6.9 %)	6 (6.9 %)	plate osteosynthesis, cerclage, cemented stem, augmentation, total exchange

- Cup displacement	1 (1.2 %)	1 (1.2 %)	cemented cup

- Inf	2 (	2 (2.3 %	exc

ection	2.3 %)	)	hange of head & inlay

- Hematoma	3 (3.5 %)	2 (2.3 %)	lavage, punction

- Thrombosis (%)	0 (0.0 %)	0 (0.0 %)	-

- Pulmonary embolism (%)	0 (0.0 %)	0 (0.0 %)	-


Demographic Data	Diabetes Medication	Frequency

Male (%)	44 (61)	OHA	39

Female (%)	28 (39)	Insulin	7

Mean age	56	OHA + Insulin	18

Median age	59	Nil	8

Mean BMI	39	HbA1c	(mmol/mol)

Median BMI	39	Mean HbA1c	67

		Median Hb A1c	57

Demographic Data	Diabetes Medication	Frequency

Mean BMI	39	HbA1c	(mmol/mol)

Median BMI	39	Mean HbA1c	67

		Median Hb A1c	57


Natural populations	Year (number of accessions)	TaFlo2-A1aMean ± SEa (number of accessions)	TaFlo2-A1bMean ± SE (number of accessions)	Mean difference ± SE	PVE (%)b TGW

TGW	GpS	TGW	GpS	TGW	GpS


Test	Occlusive patch (means)	Scotogenic lens (means)	Significance (K–S test), p value

Symptom control	9.73	9.27	0.985

Comfort	4.36	7.45	0.047

Aesthetics	2.00	9.45	<0.001

Overall assessment	4.18	8.54	<0.001

Test	Occlusive patch (means)	Scotogenic lens (means)	Significance (K–S test), p value

Aesthetics	2.00	9.45	<0.001

Overall assessment	4.18	8.54	<0.001


Assays	Treatment Group	MeanCFU Counts	Treatment Effect Group

CFU-GM	N	79.3	A

	APS	52.3		B

	TPO	50.0		B

	C	34.5			C

BFU-E	N	55.3	A

	TPO	31.2		B

	APS	22.3			C

	C	8.3				D

CFU-GEMM	N	27.7	A

	APS	19.7		B

	TPO	18.0		B

	C	8.3			C

CFU-MK	N	51.8	A

	APS	32.5		B

	TPO	37.5		B

	C	15.3			C

CFU-F	N	29.8	A

	APS	27.6	A

	TPO	19.3		B

	C	8.8			C

Assays	Treatment Group	MeanCFU Counts	Treatment Effect Group

CFU-GM	N	79.3	A

	APS	52.3		B

	TPO	50.0		B

	C	34.5			C

BFU-E	N	55.3	A

	TPO	31.2		B

	APS	22.3			C

	C	8.3

CFU-GEMM	N	27.7	A

	APS	19.7		B

	TPO	18.0		B

	C	8.3			C

CFU-MK	N	51.8	A

	APS	32.5		B

	TPO	37.5		B

	C	15.3			C

CFU-F	N	29.8	A

	APS	27.6	A

	TPO	19.3		B

	C	8.8			C


Case	Age	Disease recurrence	Presence of metastasis*	Follow-up (months)	Life status

1	41	No	No	64	Alive

2	37	No	Yes	22	Alive

3	55	NI	NI	NI	NI

4	59	No	Yes	16	Dead

5	46	No	No	107	Alive

6	27	No	No	28	Alive

7	33	Yes	No	36	Alive

8	67	No	No	34	Alive

9	40	No	No	35	Alive

10	54	No	Yes	48	Dead

11	57	Yes	No	30	Alive

12	61	No	No	9	Alive

13	67	No	No	32	Alive

14	38	No	No	17	Alive

15	71	No	No	5	Alive

16	40	No	No	87	Alive

17	40	No	No	10	Alive

18	58	No	Yes	47	Dead

19	47	No	No	22	Alive

20	41	No	No	14	Alive

21	39	No	Yes	9	Dead

22	40	No	Yes	48	Alive

23	45	No	No	35	Alive

24	53	No	Yes	13	Alive

25	29	No	Yes	14	Dead

26	36	No	Yes	19	Dead

27	24	No	Yes	6	Alive

28	48	No	Yes	NI	Dead

29	56	No	No	22	Alive

30	77	No	Yes	17	Alive

Case	Age	Disease recurrence	Presence of metastasis*	Follow-up (months)	Life status

27	24	No	Yes	6	Alive

28	48	No	Yes	NI	Dead

29	56	No	No	22	Alive

30	77	No	Yes	17	Alive


	Prior to replacement (RR*, 95% CI)	Subsequent to replacement(RR, 95% CI)

All Outdoor Injuries	1.65 (1.50-1.82)	2.07 (1.91-2.24)

Non-equipment injuries	1.68 (1.50-1.89)	2.41 (2.20-2.64)

Equipment-related injuries	1.52 (1.24-1.86)	1.13 (0.95-1.32)

	Prior to replacement (RR*, 95% CI)	Subsequent to replacement(RR, 95% CI)

Non-equipment injuries	1.68 (1.50-1.89)	2.41 (2.20-2.64)

Equipment-related injuries	1.52 (1.24-1.86)	1.13 (0.95-1.32)


Polar Bear Scaffolds	5′ LTR Location	3′ LTR Location	Overall Mean K2P Distance	Age Estimation Mya


				Cardiac infarction	Crude estimate	Age-adjusted estimate

	Age (years)	Gender	Total	Yes	No	OR (95% CI), p-value	OR (95% CI), p-value

	≥ 35	Fe		2 (2.1%	93 (97.	2.	1.5 (0.4 – 6


S-RAMM items	AUC	95% confidence interval of AUC	p	Odds ratio	95% confidence interval of OR	p


Immunocompromising conditions

Primary immunodeficiency

HIV infection

Nephrotic syndrome

Severe renal failure (GFR < 30)

Bone marrow trasplantation

Recent cancer

Immunosuppressive medication/Radiotherapy

Other high risk condition

Asplenia

Cochlear implant

CSF leaks

Chronic respiratory disease

Chronic heart disease

Liver disease

Diabetes mellitus

Alcoholism

Smoking


Recurrence

Intrahepatic recurrence	222 (76.6%)

Extrahepatic recurrence	68 (23.4%)

Main treatment for recurrence

Transplantation	10 (3.4%)

Repeat resection	29 (9.8%)

Local ablation therapy	29 (9.8%)

TACE	172 (58.1%)

Chemotherapy	26 (4.3%)

Radiation therapy	16 (5.4%)

Cause of death

Recurrent HCC	182 (80.9%)

Complication of liver cirrhosis without recurrence	25 (11.1%)

Unrelated (including perioperative death)	18 (8.0%)


	Normoxic	Hypoxic	Hypoxic + CPP

Alkaline Phosphatase	179 <underline>+</underline> 20	195 <underline>+</underline> 31	176 <underline>+</underline> 16

ALT	25 <underline>+</underline> 4	30 <underline>+</underline> 10	33 <underline>+</underline> 6

AST	48 <underline>+</underline> 3	73 <underline>+</underline> 8 *	81 <underline>+</underline> 8 *

Creatine Kinase	163 <underline>+</underline> 46	236 <underline>+</underline> 90	225 <underline>+</underline> 38

GGT	2.0 <underline>+</underline> 0.0	3.0 <underline>+</underline> 0.0	2.4 <underline>+</underline> 0.6

Albumin	2.9 <underline>+</underline> 0.1	2.9 <underline>+</underline> 0.2	2.8 <underline>+</underline> 0.1

Total Protein	5.6 <underline>+</underline> 0.2	5.2 <underline>+</underline> 0.2	5.0 <underline>+</underline> 0.1

Total Bilirubin	0.1 <underline>+</underline> 0.0	0.1 <underline>+</underline> 0.0	0.1 <underline>+</underline> 0.0

Blood Urea Nitrogen	18.8 <underline>+</underline> 2.8	26.3 <underline>+</underline> 8.4	20.0 <underline>+</underline> 2.2

	Normoxic	Hypoxic	Hypoxic + CPP

Alkaline Phosphatase	179 + 20	195 + 31	176 + 16

ALT	25 + 4	30 + 10	33 + 6

AST	48 + 3	73 + 8 *	81 + 8 *

Creati	163	2


Transient neurological symptoms	Age (years)

All	65–74 (N=3657)	75–84 (N=2618)	85+ (N=473)

N	Per cent*	N	Per cent*	N	Per cent*	N	Per cent*


	Subjects with DLCO	Subjects without DLCO	p-value

Sample size	53	20	-

Age, years*	64 (1)	61 (2)	0.16


Targets	<|P|>	<|N|>	dDFIRE	OPUS_PSP	RWplus	GOAP	ROTAS


Parameters	Present study	Verkerk et al. [16]	Tüysüz et al. [15]

Ind IV:3	Ind IV:4

Gender	M	M	3F/2M	3F/1M

Age at last examination (y.)	14	12	1.5/21/22/23/24	2.5/10.5/11/17

Head circumference	−2SD	−2SD	−1 to −2.5 SD	−2 to −4 SD

Height (cm)	157	137	NA	NA

Intellectual disability	Severe	Severe	Severe in 5/5	Severe in 3/4

Seizures	+	-	-	+

Shy character	-	-	+	+

Aggressive behavior	+	+	-	-

Stereotype laughter	-	-	+	+

Severe speech disorder	+	+	+	+

Infantile hypotonia	+	+	+	+

Hypertonia	+	+	+	+

Hyperreflexia	+	+	NA	NA

Babinski sign	+	+	+	NA

Spasticity	+	+	+	+

Club feet	-	-	+	+

Independent walking (y.)	2	4	-	+/−

Ambulation	-	-	-	-

Craniofacial features

Facial hypotonia	-	-	NA	+

Bitemporal narrowing	-	-	NA	+

Broad nasal bridge	-	-	NA	+

Bulbous nose	-	+	NA	+

Short philtrum	+	+	NA	+

Brain MR imaging	Yes	No	3/5	4/4

Widened lateral ventricles	+		+	+

Thin splenium of the CC	+		+	+

Cerebellar hypoplasia/atrophy	+		2/3	-

Parameters	Present study	Verkerk et al. [16]	Tüysüz et al. [15]

Ind IV:3

Widened lateral ventricles	+	+	+

Thin splenium of the CC	+	+	+

Cerebellar hypoplasia/atrophy	+	2/3	-


Characteristic	Value	%

Age (years)

Range	30–87

Mean ± SD (range)	60.3±15.9

Gender, n

Male	62	51.2

Female	59	48.8

Diagnosis method, n

Histological diagnosis	78	64.5

Imaging and medical history diagnosis	43	35.5

Tumor type, n

Colorectal cancer	52	43.0

Lung cancer	19	15.7

Breast cancer	14	11.6

Renal cancer	7	5.8

Gastric cancer	5	4.1

Other	24	19.8

Tumor loading, n

With	72	59.5

Without	49	40.5

Adjuvant radiotherapy and/or chemotherapy, n

With	71	58.7

Without	50	41.3


Investigator	Patient

1	DYSF 1

DYSF 2

DYSF 3

DYSF 4

DYSF 5

DYSF 6

DYSF 7

DYSF 8

2	DYSF 1

DYSF 2

DYSF 3

DYSF 4

DYSF 5

DYSF 6

DYSF 7

DYSF 8


Metagenome source	Sample	Metagenome type	Categories observedN	Shannon diversity Index (H’)	Evenness (E)

This study	Cow 2202C	Virome	20	2.192	0.732

	Cow 657	Virome	21	2.162	0.710

	Cow 1995	Virome	22	2.299	0.744

	Cow 2028	Virome	20	2.052	0.685

	Cow 2042	Virome	17	2.011	0.710

	Cow 2165	Virome	16	1.911	0.689


	Group 1	Group 2	Group 3

	Relapsing- remitting MS	Primary progressive MS	Secondary progressive MS	Healthy controls	Pediatric onset MS	Pediatric healthy controls	Pre- relapse patients	Relapse patients


Code	Test	Supported draft

INV_1_24	FISH/int	UMD (85%)

INV_1_53.3	FISH/int	UMD (94%)

INV_4_7.2	FISH/int	UMD (90%)

INV_7_103.2	FISH/int	UMD (96%)

INV_10_59.3	FISH/int	UMD (95%)

INV_14_32	FISH/int	UMD (73%)

INV_20_0	FISH/int	UMD (98%)

INV_23_0	FISH/met.	UMD

INV_26_18.8	FISH/int	UMD (75%)

INV_27_42.3	FISH/int	UMD (90%)

MDP_4_16.2	FISH/int	Btau (98%)

MDP_5_9.6	FISH/met.	UMD

MDP_7_7.6	PCR	UMD

MDP_7_43.1	PCR	-

MDP_28_0.7	PCR	UMD

DCM_2-11	FISH/met	UMD

DCM_3-13	FISH/met	Btau

DCM_3-2	FISH/met	UMD

DCM_3-22	FISH/met	UMD

DCM_7-X	FISH/met	UMD

DCM_10-1	FISH/met	UMD

DCM_10-4	FISH/met	UMD

DCM_15-X	FISH/met	UMD

DCM_27-21	FISH/met	Btau


		Allpaths-LG/	Allpaths-LG/

Scaffold sequences	Allpaths-LG	Sspace/GapClose	Sspace/GapClose/Reapr

Number	57 815	16 090	13 206

Total size, without gaps, bp	469 049 393	565 959 143	476 867 120

Total size, with gaps, bp	614 626 609	586 542 612	503 314 177

Number > 10 Kbp	10 029	8602	8348

Number > 20 Kbp	6920	6791	6647

Number > 100 Kbp	1100	1709	1304

Number > 1 Mbp	2	0	0

Longest sequence, bp	1 844 569	979 053	558 523

Average size, bp	10 631	36 454	38 112

N50 length, bp	57 726	97 266	80 946

		Allpaths-LG/	Allpaths-LG/

Scaffold sequences	Allpaths-LG	Sspace/GapClose	Sspace/GapClose/Reapr

L50 count	2595	1792	1906

GC %	33.63	33.57	33.62


Process Type	processes	instances	Time	Total ($)

Blast	21945	100	40 hours 0 mins	$ 3,680

Ortholog Estimation	281160	100	28 hours 21 mins	$ 2,622


	Odds ratio	95% Confidence interval	P value

Predictors of AKI

Log angiopoietin-2	4.41	2.02–9.63	<0.0001

Log osteoprotegerin	1.98	1.02–3.82	0.043

Agea	1.07	1.04–1.10	<0.0001

Predictor of severe malaria

Log angiopoietin-2	5.35	2.01–14.25	0.001

Log osteoprotegerin	2.66	1.15–6.14	0.022

Log parasite count	1.47	1.15–1.89	0.002

	Odds ratio

Predictors of AKI

Log angiopoietin-2	4.41

Log osteoprotegerin	1.98

Agea	1.07

Predictor of severe malaria

Log angiopoietin-2	5.35

Log osteoprotegerin	2.66

Log parasite count	1.47


Any enteric pathogen	Campylobacter spp.	Giardia spp.	Pathogenic Escherichia coli†


Pathway	TF	miRNA

Activin	TP53	miR-143

AKT	MYC	miR-145

ALK	GATA4	miR-187

ATM	SMAD1	miR-296

BMI1	ESRRB	miR-301

BMP	SOX2	miR-21

Cell cycle	NANOG	let-7a

EGF/EGFR	KLF4	miR-371

ERBB2	MYB	miR-372

ERK	MYCN	miR-373

FGF	ZFX	miR-367

Glycolysis	STAT3	miR-302a

Hippo	ZIC3	miR-302a*

IGF	ZFP42	miR-302b

JAK/STAT	SALL4	miR-302b*

c-KIT	REST	miR-302c

Lefty	TCF3	miR-302c*

LIF	HOXB1	miR-302d

MAPK	HAND1	miR-200c

MEK/ERK	POU5F1	miR-222

NF-κB	SRY

NHEJ/HR a	TBX5

Nodal	E2F4

Notch	GATA6

p53	PAX6

PRC2	TCF4

PDGF	FOXD3

PI3K	CNOT3

PTEN	ZEB2

RAS	ESX1L

RTK

Hedgehog (SHH)

Smad

Stat3

Telomerase

TGFβ

VEGF

WNT

Pathway	TF	miRNA

AKT	MYC	miR-145

ALK	GATA4	miR-187

ATM	SMAD1	miR-296

BMI1	ESRRB	miR-301

BMP	SOX2	miR-21

Cell cycle	NANOG	let-7a

EGF/EGFR	KLF4	miR-371

ERBB2	MYB	miR-372

ERK	MYCN	miR-373

FGF	ZFX	miR-367

Glycolysis	STAT3	miR-302a

Hippo	ZIC3	miR-302a*

IGF	ZFP42	miR-302b

JAK/STAT	SALL4	miR-302b*

c-KIT	REST	miR-302c

Lefty	TCF3	miR-302c*

LIF	HOXB1	miR-302d

MAPK	HAND1	miR-200c

MEK/ERK	POU5F1	miR-222

NF-κB	SRY

NHEJ/HR a	TBX5

Nodal	E2F4

Notch	GATA6

p53	PAX6

PRC2	TCF4

PDGF	FOXD3

PI3K	CNOT3

PTEN	ZEB2

RAS	ESX1L

RTK

Hedgehog (SHH)

Smad

Stat3

Telomerase

TGFβ

VEGF

WNT


Variable	Dextrose75 g	Dextrose150 g	Lipid33 g	Lipid66 g

Kilocalories	2023 ± 237	2354 ± 242	1983 ± 206	1789 ± 181

Protein (g)	92 ± 11	102 ± 9	95 ± 13	88 ± 16

Carbohydrate (g)	261 ± 39	315 ± 41	248 ± 31	247 ± 33

F		8	72 ± 13	57 ±

Variable	Dextrose75 g	Dextrose150 g	Lipid33 g	Lipid66 g

at (g)	72 ± 11	1 ± 12		9

Vitamin C (mg)	64 ± 26	47 ± 11	40 ± 7	51 ± 13

Vitamin E (mg)	4 ± 2	4 ± 1	3 ± 1	3 ± 1

Vitamin A (RE)	267 ± 82	374 ± 110	228 ± 113	236 ± 102


Parameter	Shams	Exposure to AO nanowhiskers for:

2 wks	4 wks

Total cells/mouse, n x 103	74.0 ± 7.9	171.6 ± 19.7 **	440.3 ± 33.6 ***

Total protein, μg/mL	107.7 ± 4.7	108.0 ± 1.5	101.2 ± 2.7

LDH activity, U/L	180 ± 18	146 ± 17	191 ± 10


Gram	Bacterial strain	Concentration of SS-capped AgNPs (mM)	MIC (mM)

 	 	0.001	0.004	0.008	0.017	0.034

+	MRSA	T	T/C	C	C	C	0.008

+	S. aureus	T	T/C	C	C	C	0.008

+	B. subtilis	T	T/C	C	C	C	0.008

−	P. aeruginosa	T	C	C	C	C	0.004

−	A. baumannii	C	C	C	C	C	0.001

−	E. coli	T	C	C	C	C	0.004


ACE genotype	II

Percent body fat category	Normal fat(n = 30)

SBP (mmHg)	103.2 (1.3)*

DBP (mmHg)	68.6 (1.1)


	TCPC (n = 6)	TCPC + AVR (n = 4)

Morphology of AV valve

 SAVV (morphologically tricuspid valve)	5 (83 %)	0

 CAAV	1 (17 %) early death	4 (100 %)

Degree of AV valve regurgitation

 Slight	3 (50 %)	0

 Mild	3 (50 %)	0

 Moderate	0	2 (50 %)

 Severe	0	2 (50 %)

Early mortality	1	0

	TCPC (n = 6)

Morphology of AV valve

SAVV (morphologically tricuspid valve)	5 (83 %)

CAAV	1 (17 %) early death

Degree of AV valve regurgitation

Slight	3 (50 %)

Mild	3 (50 %)

Moderate	0

Severe	0

Early mortality	1

TCPC + AVR (n = 4)

Morphology of AV valve

0

4 (100 %)

Degree of AV valve regurgitation

0

0

2 (50 %)

2 (50 %)

0


Patient	1	2	3	4

Age at onset (y)	6	1	0.8	2

Age at diagnosis* (y)	10	6	11	5

Present age (y)	13	8	15	Died at 8 Y

Family history	+	+	-	-

First symptom	Septicemia	Otitis media	Otitis media	Otitis media

Otitis media	+	+	+	+

Sinusitis	+	-	+	-

Pneumonia	+	+	+	+

Bronchiectasis	+	-	+	-

Arthritis	+	-	-	+

Skin infection	+	+	-	-

Septicemia	+	+	+	+

Meningitis/encephalitis	+	-	+	-

Recurrent diarrhea	-	-	-	+

Tonsils	Absent	Hypoplastic	Absent	Hypoplastic

Duration of IVIG treatment (m)	25	17	33	12

Patient	1	2	3	4

Age at onset (y)	6	1	0.8	2

Age at diagnosis* (y)	10	6	11	5

Present age (y)	13	8	15	Died at 8 Y

Family history	+	+	-	-

First symptom	Septicemia	Otitis media	Otitis media	Otitis media

Otitis media	+	+	+	+

Sinusitis	+	-	+	-

Pneumonia	+	+	+	+

Bronchiectasis	+	-	+	-

Arthritis	+	-	-	+

Skin infection	+	+	-	-

Septicemia	+	+	+	+

Meningitis/encephalitis	+	-	+	-

Recurrent diarrhea	-	-	-	+

	Absen	Hy	A	H

Patient	1	2	3	4

Tonsils	t	poplastic	bsent	ypoplastic

Duration of IVIG treatment (m)	25	17	33	12


Gene Set	Number of Genes	Categorized Genes	p-Value

Galactose metabolism	16	Gck	<0.0001

Cysteine metabolism	16	Sult1c2	0.003

Aminoacyl-tRNA biosynthesis	16	Vars2	0.009

Wnt signaling pathway	112	Sox17Dkk2 *	0.014

Taste transduction	29	Gnat3 *Tas2r114	0.046

C21-Steroid hormone metabolism	10	Cyp21a1	0.1250

Chondroitin sulfate biosynthesis	14	B3gat2Chst12	0.1260

Antigen processing and presentation	58	RT1-Aw2	0.163


Primer	Forward	Reverse

IFN-γ	GGTCAACAACCCACAGGTCC	CGACTCCTTTTCCGCTTCC

IL-4	TCTCGAATGTACCAGGAGCCATATC	AGCACCTTGGAAGCCCTACAGA

IL-10	GCTCCTAGAGCTGCGGACT	TGTTGTCCAGCTGGTCCTTT

IL-17A	AGGACGCGCAAACATGAGTC	TTGGACACGCTGAGCTTTGAG

TGF-β	CTGGATACCAACTACTGCTTCAG	TTGGTTGTAGAGGGCAAGGACCT

Foxp3	ACACCCAGGAAAGACAGCAAC	CTCGAAGACCTTCTCACAACCAG

GAPDH	CAACTTTGGCATTGTGGAAGG	ACACATTGGGGGTAGGAACAC

Primer	Forward	Reverse

GAPDH	CAACTTTGGCATTGTGGAAGG	ACACATTGGGGGTAGGAACAC


Aspects	Score/question

1. Risk factors associated with obstetric fistula	1

 - Early pregnancy	0.125

 - Home delivery	0.125

 - Female Genital Mutilation	0.125

 - Evil spirits	0.125

 - Breach of a prohibited act	0.125

 - Prolonged labour	0.125

 - Bad luck	0.125

 - Malnutrition of the mother	0.125

2. Symptoms of obstetric fistula	1

 - Urinary incontinence	0.2

 - Faecal incontinence	0.2

 - Continuous sleeping	0.2

 - Stomach ache	0.2

 - Vulva irritation	0.2

3. Duration of normal labour	1

4. Source of emergency obstetric care	1

Total	4


Standard Deviation (change)	Treatment Change	N per group	N total

18	20	14	28


Patients’ characteristics

Industrial sector

Age (years)

Smoking (pack-years)

Sex

Chronic Sinusitis

Allergies

Site of onset

ADC subtype


	sense	antisense

#1	GTATCTGCACTCTCAATCAGGAGC	AAACTGTAACCCCTATCTCTACTCAC

#2	CCTGGGTTTCCACCATATGCTTTC	AGTTCCTTGCACTCCTGTTAACAA

#3	CCTGGGTTTCCACCATATGCTTTC	GGTCGCCTAGTGTCATGACCA

#4	GACCACATCCCAACCGAATC	CACAGGCCAGACTGACACCC

#5	GACCACATCCCAACCGAATC	CTGACACCCAGTAGTGAAGG

#6	GATAGCAGCCGCAGAAGAGC	CCACCTGGGTTTCCACCATA

	sense	antisense

#1	GTATCTGCACTCTCAATCAGGAGC	AAACTGTAACCCCTATCTCTACTCAC

#2	CCTGGGTTTCCACCATATGCTTTC	AGTTCCTTGCACTCCTGTTAACAA

#3	CCTGGGTTTCCACCAT	GGTCG

	ATGCTTTC	CCTAGTGTCATGACCA

#4	GACCACATCCCAACCGAATC	CACAGGCCAGACTGACACCC

#5	GACCACATCCCAACCGAATC	CTGACACCCAGTAGTGAAGG

#6	GATAGCAGCCGCAGAAGAGC	CCACCTGGGTTTCCACCATA


Commercial laboratory variable	Mean change younger cohort	Mean change older cohort	p-value

CD3%	−2.75	2.33	0.036

CD4%	−2.50	1.67	0.028

WBC	2.13	−0.70	0.031

IgA	4.25	−13.17	0.059

Zinc/Copper Ratio	−0.08	0.13	0.061


Strain	Source	Accession no.	Genome size (bp)	N50 (bp)	No. of scaffolds (>300 bp)	G+C content (%)

Arcobacter sp. AF1028	Human feces	JART00000000	2,414,790	148,259	46	27.24

Arcobacter sp. AF1078	Human feces	JARS00000000	2,496,885	127,252	53	27.18

Strain	Source	Accession no.	Genome size (bp)	N50 (bp)	No. of scaffolds (>300 bp)	G+C content (%)

Arcobacter sp. AF1078	Human feces	JARS00000000	2,496,885	127,252	53	27.18


	All articles (n=168)	Including NEJM protocols (n=61)

Characteristics	n (%)	n (%)

Journal

 NEJM	61 (36)	61

 Lancet	64 (38)

 JAMA	19 (11)

 BMJ	8 (5)

 Annals of Internal Medicine	5 (2)

 PLoS Medicine	7 (4)

 Archives of Internal Medicine	2 (1)

 JAMA of Internal Medicine	2 (1)

Year of publication

 2010	26 (15)	9 (15)

 2011	27 (16)	9 (15)

 2012	29 (17)	8 (13)

 2013	39 (23)	19 (31)

 2014	27 (16)	10 (16)

 2015	20 (12)	6 (10)

Type of intervention

 Drug	112 (67)	44 (72)

 Surgery	22 (13)	7 (11)

 Other	34 (20)	10 (16)

Randomisation

 Patient	163 (97)	59 (97)

 Cluster	5 (3)	2 (3)

Power

 80%	6 (36)	19 (31)

 85%	11 (7)	5 (8)

 90%	65 (39)	26 (43)

 71–99% (excluding the above)	21 (12)	11 (18)

 Not reported/unclear	10 (6)	0

Composite outcome

 Yes	78 (46)	37 (61)

 No	90 (54)	24 (39)

Disease

 Heart disease	30 (18)	13 (21)

 Blood disorder	19 (11)	6 (10)

 Cancer	16 (10)	8 (13)

 Diabetes	11 (7)	2 (3)

 Thromboembolism	6 (4)	6 (10)

 Skin infection (non-contagious)	3 (2)	2 (3)

 Urinary tract infection	3 (2)	0

 Arthritis	3 (2)	1 (2)

 Opthomology	3 (2)	1 (2)

 Pneumonia	3 (2)	1 (2)

 Complications in pregnancy	3 (2)	0

 Stroke	3 (2)	2 (3)

 Testing method	3 (2)	1 (2)

 Appendicitis	2 (1)	1 (2)

 Depression	2 (1)	0

 Other non-infectious disease	18 (11)	7 (11)

 HIV	18 (11)	2 (3)

 Tuberculosis	6 (4)	4 (7)

 Malaria	4 (2)	1 (2)

 Skin infection (contagious)	2 (1)	0

 Hepatitis C	2 (1)	2 (3)

 Other infectious disease	8 (5)	1 (2)

	All articles (n=168)

Characteristics	n (%)

Journal

NEJM	61 (36)

Lancet	64 (38)

JAMA	19 (11)

BMJ	8 (5)

Annals of Internal Medicine	5 (2)

PLoS Medicine	7 (4)

Archives of Internal Medicine	2 (1)

JAMA of Internal Medicine	2 (1)

Year of publication

2010	26 (15)

2011	27 (16)

2012	29 (17)

2013	39 (23)

2014	27 (16)

2015	20 (12)

Type of intervention

Drug	112 (67)

Surgery	22 (13)

Other	34 (20)

Randomisation

Patient	163 (97)

Cluster	5 (3)

Power

80%	6 (36)

85%	11 (7)

90%	65 (39)

71–99% (excluding the above)	21 (12)

Not reported/unclear	10 (6)

Composite outcome

Yes	78 (46)

No	90 (54)

Disease

Heart disease	30 (18)

Blood disorder	19 (11)

Cancer	16 (10)

Diabetes	11 (7)

Thromboembolism	6 (4)

Skin infection (non-contagious)	3 (2)

Urinary tract infection	3 (2)

Arthritis	3 (2)

Opthomology	3 (2)

Pneumonia	3 (2)

Complications in pregnancy	3 (2)

Stroke	3 (2)

Testing method	3 (2)

Appendicitis	2 (1)

Depression	2 (1)

Other non-infectious disease	18 (11)

HIV	18 (11)

Tuberculosis	6 (4)

Malaria	4 (2)

Skin infection (contagious)	2 (1)

Hepatitis C	2 (1)

Other infectious disease	8 (5)


Author	Study design	Oral health criteria	Study population	Results

Bundgaard et al. (85)	Case-control	Missing teeth	161 patients and 400 controls (Denmark)	Significantly increased risk of developing oral SCCA for patients with fewer than 15 teeth

Rezende et al. (86)	Case-control	CPITNa and DMFTb	50 patients and 50 controls (Cuba)	76% of subjects in cancer group showed greater than 6 mm pockets compared to 10% of control group

Garrote et al. (87)	Case-control	Missing teeth	200 patients and controls (Cuba)	Significantly increased risk of oral cancer for patients missing 16 or more teeth

Hiraki et al. (88)	Case-control	Missing teeth	429 patients and 10,480 controls (Japan)	Significantly increased risk of head and neck cancer with decreased number remaining teeth

Marshall et al. (89)	Case-control	Missing teeth	290 patients and controls (United States)	Significantly increased risk of oral cancer with loss of 11 or more teeth

Michaud et al. (90)	Cohort	Self-reported history of periodontal disease (confirmed by radiographs and missing teeth)	118 patients (United States)	No significant increase in risk for oropharyngeal cancer with history of periodontal disease or increased number of tooth loss

Rosenquist et al. (91)	Case-control	Missing teeth	132 patients and 320 controls (Sweden)	Significantly increased risk of oral and oropharyngeal cancer for missing over 20 teeth

Tezal et al. (92)	Cohort	Clinical attachment loss (CAL)	131 oral tumors and 323 oral pre-cancerous lesions (United States)	Significantly increased risk of oral tumor and pre-cancerous lesion with >1.5 mm clinical attachment loss

Tezal et al. (81)	Case-control	Alveolar bone loss	51 cases and 54 controls (United States)	Significantly increased risk of tongue cancer with increased alveolar bone loss

Tezal et al. (82)	Case-control	Alveolar bone loss	266 patients and 207 controls (United States)	Significantly increased risk of oral cavity SCC with periodontitis

Tezal et al. (93)	Case-control	Alveolar bone loss	124 head and neck SCC patients (United States)	Periodontitis is associated with tumor HPV status

Wen et al. (94)	Cohort	Medical records from insurance claims	96,375 gingivitis and 51,791 periodontitis cases (Taiwan)	Significantly increased risk of oral cancer with the history of periodontitis

Zheng et al. (95)	Case-control	Missing teeth	404 subjects and controls (United States)	Significantly increased risk of oral cancer with increased missing teeth

Author	Study design	Oral health criteria	Study population	Results

Bundgaard et al. (85)	Case-control	Missing teeth	161 patients and 400 controls (Denmark)	Significantly increased risk of developing oral SCCA for patients with fewer than 15 teeth

Rezende et al. (86)	Case-control	CPITNa and DMFTb	50 patients and 50 controls (Cuba)	76% of subjects in cancer group showed greater than 6 mm pockets compared to 10% of control group

Garrote et al. (87)	Case-control	Missing teeth	200 patients and controls (Cuba)	Significantly increased risk of oral cancer for patients missing 16 or more teeth

Hiraki et al. (88)	Case-control	Missing teeth	429 patients and 10,480 controls (Japan)	Significantly increased risk of head and neck cancer with decreased number remaining teeth

Marshall et al. (89)	Case-control	Missing teeth	290 patients and controls (United States)	Significantly increased risk of oral cancer with loss of 11 or more teeth

Michaud et al. (90)	Cohort	Self-reported history of periodontal disease (confirmed by radiographs and missing teeth)	118 patients (United States)	No significant increase in risk for oropharyngeal cancer with history of periodontal disease or increased number of tooth loss

Rosenquist et al. (91)	Case-control	Missing teeth	132 patients and 320 controls (Sweden)	Significantly increased risk of oral and oropharyngeal cancer for missing over 20 teeth

Tezal et a	Cohor	Clinica	131 oral tumors and 323 oral pre-c	Significantly increased risk of oral tumor and pre-cancerous lesion with >1.5 mm

Author	Study design	Oral health criteria	Study population	Results

l. (92)	t	l attachment loss (CAL)	ancerous lesions (United States)	clinical attachment loss

Tezal et al. (81)	Case-control	Alveolar bone loss	51 cases and 54 controls (United States)	Significantly increased risk of tongue cancer with increased alveolar bone loss

Tezal et al. (82)	Case-control	Alveolar bone loss	266 patients and 207 controls (United States)	Significantly increased risk of oral cavity SCC with periodontitis

Tezal et al. (93)	Case-control	Alveolar bone loss	124 head and neck SCC patients (United States)	Periodontitis is associated with tumor HPV status

Wen et al. (94)	Cohort	Medical records from insurance claims	96,375 gingivitis and 51,791 periodontitis cases (Taiwan)	Significantly increased risk of oral cancer with the history of periodontitis

Zheng et al. (95)	Case-control	Missing teeth	404 subjects and controls (United States)	Significantly increased risk of oral cancer with increased missing teeth


Injure	1-4 y	5-9 y	10-14 y

Transport accidents	21(47.7)	23(39.7)	45(51.7)

Accidental drowning and submersion	2(4.5)	17(29.3)	28(32.2)


Characteristic	Patients (n= 19)(%)

Sex (males/females)	12/7

Age, years, median (range)	54 (30–75)

Underlying liver disease

Hepatitis B virus	11 (57.89)

Alcoholic	3 (15.79)

Autoimmune hepatitis	1 (5.26)

Hybrid cause	4 (21.05)

Basic underlying disease

Cardiovascular disease	4 (21.05)

Diabetes mellitus type 2	2 (10.53)

Chronic lung diseases	2 (10.53)

Complications

Hepatic encephalopathy	8 (42.10)

Hepatic renal syndrome	4 (21.05)

Upper gastric bleeding	4 (21.05)

Ascites	16 (84.21)

Hydrothorax	10 (52.63)

Hepatic carcinoma	2 (10.53)

CTP scores (mean ± SD)	11 ± 2

Child B	6 (31.58)

Child C	13 (68.42)

MELD (mean ± SD)	22 ± 7

Neutropenia	2 (10.53)

Broad-spectrum antibiotics usage	18 (94.74)

One antibiotic	9 (47.37)

Two antibiotics	4 (21.05)

Three antibiotics	5 (26.32)

Steroids exposure(longer than 1 week)	11 (57.89)

Survival rate

1 month	5/19

3 month	4/19

Characteristic	Patients (n= 19)(%)

Child B	6 (31.58)

Child C	13 (68.42)

MELD (mean ± SD)	22 ± 7

Neutropenia	2 (10.53)

Broad-spectrum antibiotics usage	18 (94.74)

One antibiotic	9 (47.37)

Two antibiotics	4 (21.05)

Three antibiotics	5 (26.32)

Steroids exposure(longer than 1 week)	11 (57.89)

Survival rate

1 month	5/19

3 month	4/19


	Mean	Median	Min	Max

% of Patients Who Should Receive DES, 1st Year Following Approval

Bare metal stent patients	42.8%	30.0%	5.1%	100.0%

CABG patients	16.8%	10.0%	5.0%	50.0%

% of Patients Who Should Receive DES, 2nd Year Following Approval

Bare metal stent patients	56.0%	50.0%	10.2%	100.0%

CABG patients	25.5%	20.0%	5.0%	80.0%

% of Patients Who Should Receive DES, 3rd Year Following Approval

Bare metal stent patients	70.1%	90.0%	30.0%	100.0%

CABG patients	31.4%	30.0%	5.0%	90.0%

% of Patients Who Should Receive DES, 4th Year Following Approval

Bare metal stent patients	79.7%	90.0%	40.6%	100.0%

CABG patients	37.8%	35.0%	5.0%	90.0%

% of Patients Who Should Receive DES, 5th Year Following Approval

Bare metal stent patients	86.8%	90.0%	60.8%	100.0%

CABG patients	43.7%	40.0%	5.0%	90.0%


Job satisfaction domains	Level of satisfaction

Satisfied	Dissatisfied

N (%)	N (%)

Leadership and planning	175 (43.2)	230 (56.8)

Culture and communications	180 (44.6)	225 (55.4)

Employee’s role	211 (52.1)	194 (47.9)

Work environment	178 (43.9)	227 (56.1)

Relationship with supervisor	163 (40.2)	242 (59.8)

Training and development	165 (41.4)	237 (58.6)

Pay and benefits	148 (36.5)	257 (63.5)

Coworker relation ship	209 (51.6)	196 (48.4)

Overall satisfaction	179 (44.2)	226 (55.8)


Activity and Level	No.	Model 1a

B	95% CI

Attendance at sports/PA clubs

Low	2,333	0	Referent

Medium	2,299	2.0	1.5, 2.6

High	3,830	3.4	2.9, 3.9

Sports/PA with siblings

Low	945	0	Referent

Medium	1,887	0.8	0.1, 1.6

High	5,630	−0.4	−1.0, 0.3

Sports/PA with parents

Low	1,824

Medium	3,090	1.1	0.6, 1.7

High	3,548	0.4	−0.1, 1.0

Park/playground visits

Low	1,513	0	Referent

Medium	2,690	0.7	0.1, 1.3

High	4,259	−0.5	0.1, 1.0


Cy-3-G (μmol/L)	Papp (×10−7 cm/s)	Efflux Ratio	Transport Efficiency (%)

B → A	A → B


Outcomes	Support (N = 105)	Control (N = 107)	RR (95%CI)	p value

Apgar score at 1 minute < 7	20	21	0.97 (0.56–1.68)	0.915

Apgar score at 5 minutes < 7	3	2	1.53 (0.26–8.96)	0.681*

Birthweight (g) (mean ± SD 95%)	3.197 (2.360–4.245)	3.246 (2.410–4.145)	-	0.370¶

Admission to NICU	5	6	0.91 (0.47–1.77)	0.781

Immediate contact mother/newborn	52	41	1.29 (0.95–1.76)	0.100

Time of contact mother/newborn (min) (mean ± 95% SD)	25.1 (10–55)	22.7 (10–40)	-	0.360†

Takes breast/suckles in delivery room	12	7	1.75 (0.72–4.26)	0.213

Takes breast/suckles (12 h following birth)	99	100	1.08 (0.59–1.97)	0.801

Breast fissure	7	6	1.19 (0.41–3.42)	0.747

Number of breast-feeds 12 hours following birth (mean)	4.3 (0–12)	4.4 (0–10)	-	0.589†

Outcomes

Apgar score at 1 minute < 7

Apgar score at 5 minutes < 7

Birthweight (g) (mean ± SD 95%)

Admission to NICU

Immediate contact mother/newborn

Time of contact mother/newborn (min) (mean ± 95% SD)

Takes breast/suckles in delivery room

Takes breast/suckles (12 h following birth)

Breast fissure

Number of breast-feeds 12 hours following birth (mean)


Method	Precision (%)	Recall (%)	F-score (%)

hHMM	98.5 ± 0.4	93.5 ± 1.9	95.9 ± 0.9


Risk factor	Intervention options if risk factor identified

History of falls/falls injuries	Referral to GPAppropriate acute management if injury recent

Medications (number)	Refer to GP for medication review

Medications (associated with increased falls risk)	Refer to GP/specialist for medication review

Medical conditions (associated with increased falls risk)	Refer to GP/specialist for review

Sensory loss: vision	Brochure on lighting and home safetyRefer to optometristRefer to Ophthalmologist via GPRefer to Vision Australia (includes mobility training and aids for visually impaired)Refer to OT for home assessmentRefer to GP

Sensory loss: hearing	Refer to audiologist

Sensory loss: somatosensory	Refer to podiatristRefer to GP

Feet and footwear	Refer to podiatristProvide information about good footwear and falls prevention

Cognitive status	Refer to GPMemory Clinic referral in consultation with GP if memory problems have not been investigatedReferral to OT for strategies to facilitate memory and/or home assessment

Continence	Refer to GPContinence clinic referralRefer to physiotherapistRefer for OT home assessment/functional assessment, including need for commode

Nutritional status	Provide brochure on nutritionRefer to dieticianGP referral

Environment	Provide with information pamphlet on safety in the homeRefer for OT home assessment/functional assessment and training

Function	Refer to OT for home assessment/functional assessment and trainingRefer to Physiotherapist for assessment and exercise to improve functionReferral for support services

Functional behaviour	Refer to physiotherapist, OT, GP

Balance	Home exercise programReferral to PhysiotherapistReferral for OT for a home assessmentReferral to GP for further investigation

Gait and physical activity	Home exercise programReferral to PhysiotherapistReferral for OT home assessment/functional assessment and trainingBrochure on tips for walking

Osteoporosis risk	Refer to GP for consideration of calcium and/or vitamin D supplementsRefer to dieticianHip protectors

Additional options for preventing falls injury	Hip protectorsPersonal alarm

Risk factor

History of falls/falls injuries

Medications (number)

Medications (associated with increased falls risk)

Medical conditions (associated with increased falls risk)

Sensory loss: vision

Sensory loss: hearing

Sensory loss: somatosensory

Feet and footwear

Cognitive status

Continence

Nutritional status

Environment

Function

Functional behaviour

Balance

Gait and physical activity

Osteoporosis risk

Additional options for preventing falls injury

Intervention options if risk factor identified

Referral to GPAppropriate acute management if injury recent

Refer to GP for medication review

Refer to GP/specialist for medication review

Refer to GP/specialist for review

Brochure on lighting and home safetyRefer to optometristRefer to Ophthalmologist via GPRefer to Vision Australia (includes mobility training and aids for visually impaired)Refer to OT for home assessmentRefer to GP

Refer to audiologist

Refer to podiatristRefer to GP

Refer to podiatristProvide information about good footwear and falls prevention

Refer to GPMemory Clinic referral in consultation with GP if memory problems have not been investigatedReferral to OT for strategies to facilitate memory and/or home assessment

Refer to GPContinence clinic referralRefer to physiotherapistRefer for OT home assessment/functional assessment, including need for commode

Provide brochure on nutritionRefer to dieticianGP referral

Provide with information pamphlet on safety in the homeRefer for OT home assessment/functional assessment and training

Refer to OT for home assessment/functional assessment and trainingRefer to Physiotherapist for assessment and exercise to improve functionReferral for support services

Refer to physiotherapist, OT, GP

Home exercise programReferral to PhysiotherapistReferral for OT for a home assessmentReferral to GP for further investigation

Home exercise programReferral to PhysiotherapistReferral for OT home assessment/functional assessment and trainingBrochure on tips for walking

Refer to GP for consideration of calcium and/or vitamin D supplementsRefer to dieticianHip protectors

Hip protectorsPersonal alarm


Patient #	Sex	Age(year)	Injected activity (MBq)	Diagnosis

1	M	2	320	Mediastinum 7-cm diameter NET

2	F	7	450

3	M	11	490	Right adrenal pheochromocytoma (only shown in SPECT/CT image)

4-Aa	F	12	500

5	F	12	600

4-Ba	F	13	450

6	F	13	480	Appendix NET, area of accumulation above the uterus

7	F	14	600	MEN-1, head of the pancreas NET and lymph node accumulation on the left side

8	M	14	940

9	F	16	500

10	F	16	600

11	M	17	720	MEN-1, head of the pancreas insulinoma

Patient #	Sex	Age(year)	Injected activity (MBq)	Diagnosis

6	F	13	480	Appendix NET, area of accumulation above the uterus

7	F	14	600	MEN-1, head of the pancreas NET and lymph node accumulation on the left side

8	M	14	940

9	F	16	500

10	F	16	600

11	M	17	720	MEN-1, head of the pancreas insulinoma


Cell line	Media	Comment

1. 293	DMEM	Embryonic kidney

2. A549	DMEM	Adenocarcinomic alveolar basal epithelial

3. C33a	DMEM	Cervical carcinoma

4. DUT145	DMEM	Prostate cancer

5. H1229	RPMI	Lung carcinoma

6. HaCAT	RPMI	Immortalized, non-tumorigenic keratinocyte

7. HCT116	McCoy 5A	Colorectal carcinoma

8. HeLa	Joklik	Cervical carcinoma

9. hESC2	DMEM	Human embryonic stem cells

10. HFF	DMEM	Human foreskin fibroblasts

11. HL60	IMM	Promyelocytic leukemia cells

13. Huh7.0	DMEM	Hepatocarcinoma

14. Huh7.5	DMEM	Hepatocarcinoma (RIG-I-deficient)

14. MCF7	DMEM	Breast carcinoma

15. MDaMB231	L15	Breast carcinoma

16. Mdm13	DMEM	Monocyte-derived macrophages

17. NB4	RPMI	Acute promyelocytic cell line

18. PANC1	DMEM	Pancreatic carcinoma, epithelial-like

19. PC3	DMEM	Prostate cancer

20. SAOS	McCoy 5A	Epithelial-like osteosarcoma cell line

21. SW480	L15	Colon adenocarcinoma

22. U2OS	DMEM	Osteosarcoma

23. U251	DMEM	Glioblastoma

24. U937	RPMI	Leukemic monocyte lymphoma

Cell line	Media

1. 293	DMEM

2. A549	DMEM

3. C33a	DMEM

4. DUT145	DMEM

5. H1229	RPMI

6. HaCAT	RPMI

7. HCT116	McCoy 5A

8. HeLa	Joklik

9. hESC2	DMEM

10. HFF	DMEM

11. HL60	IMM

13. Huh7.0	DMEM

14. Huh7.5	DMEM

14. MCF7	DMEM

15. MDaMB231	L15

16. Mdm13	DMEM

17. NB4	RPMI

18. PANC1	DMEM

19. PC3	DMEM

20. SAOS	McCoy 5A

21. SW480	L15

22. U2OS	DMEM

23. U251	DMEM

24. U937	RPMI

Comment

Embryonic kidney

Adenocarcinomic alveolar basal epithelial

Cervical carcinoma

Prostate cancer

Lung carcinoma

Immortalized, non-tumorigenic keratinocyte

Colorectal carcinoma

Cervical carcinoma

Human embryonic stem cells

Human foreskin fibroblasts

Promyelocytic leukemia cells

Hepatocarcinoma

Hepatocarcinoma (RIG-I-deficient)

Breast carcinoma

Breast carcinoma

Monocyte-derived macrophages

Acute promyelocytic cell line

Pancreatic carcinoma, epithelial-like

Prostate cancer

Epithelial-like osteosarcoma cell line

Colon adenocarcinoma

Osteosarcoma

Glioblastoma

Leukemic monocyte lymphoma


Gene abbreviationa	Gene symbola	Accession no.b	Gene description	Gene group	Z-Testc	Ratiod	95% CIe

Up-regulated gene expression

 TECK/CCL25	Scya25	NM_009138	small inducible cytokine A25	Chemokine	1.5 × 10–14	4.2	6.2–2.9

 Mdk	Mdk	NM_010784	midkine	Neurotrophic group	2.9 × 10–7	3.0	4.7–1.9

 IL-5	Il5	NM_010558	interleukin 5	Interleukin	9.5 × 10–4	1.9	2.9–1.3

 VEGF-A	Vegf	NM_009505	vascular endothelial growth factor	Angiogenic factor	2.5 × 10–5	1.8	2.2–1.4

Down-regulated gene expression

 EphA3	Epha3	M68513	eph-related receptor tyrosine kinase (Mek4)	Eph family	4.0 × 10–8	0.5	0.6–0.4

 CCR-4	Cmkbr4	NM_009916	chemokine (C-C) receptor 4	Chemokine receptor	1.8 × 10–5	0.6	0.8–0.5

 LIF	Lif	NM_008501	leukemia inhibitory factor	Cytokine and receptors	3.0 × 10–5	0.6	0.8–0.4

 GDF-7	Gdf7	U08339	BALB/c putative growth factor GDF7 (Gdf7) gene	TGF-beta superfamily	2.4 × 10–4	0.5	0.7–0.3

 EBF	Ebf	NM_007897	early B-cell factor	Signal transduction	3.7 × 10–4	0.5	0.7–0.4

 CD27/TNFRSF7	Tnfrsf7	L24495	CD27 antigen	TNF superfamily	6.4 × 10–4	0.6	0.8–0.4

 SLIT-3	Slit3	AF088902	SLIT1 protein	Developmental factor	9.2 × 10–4	0.7	0.8–0.5

 CX3CL1	Scyd1	NM_009142	small inducible cytokine subfamily D, 1	Chemokine	1.2 × 10–3	0.4	0.7–0.2

 SMAD1	Madh1	NM_008539	MAD homolog 1 (Drosophila)	Signal transduction	1.3 × 10–3	0.6	0.8–0.5

 A1	Bcl2a1a	L16462	hemopoietic-specific early response protein	Apoptosis related	1.5 × 10–3	0.6	0.8–0.4

Gene abbreviationa	Gene symbola	Accession no.b	Gene description	Gene group	Z-Testc	Ratiod	95% CIe

Up-regulated gene expression

TECK/CCL25	Scya25	NM_009138	small inducible cytokine A25	Chemokine	1.5 × 10–14	4.2	6.2–2.9

Mdk	Mdk	NM_010784	midkine	Neurotrophic group	2.9 × 10–7	3.0	4.7–1.9

IL		NM_010558	interleukin	Interl	9.5 ×	1.9	2.9–1.3

-5	Il5		 5	eukin	 10–4

VEGF-A	Vegf	NM_009505	vascular endothelial growth factor	Angiogenic factor	2.5 × 10–5	1.8	2.2–1.4

Down-regulated gene expression

EphA3	Epha3	M68513	eph-related receptor tyrosine kinase (Mek4)	Eph family	4.0 × 10–8	0.5	0.6–0.4

CCR-4	Cmkbr4	NM_009916	chemokine (C-C) receptor 4	Chemokine receptor	1.8 × 10–5	0.6	0.8–0.5

LIF	Lif	NM_008501	leukemia inhibitory factor	Cytokine and receptors	3.0 × 10–5	0.6	0.8–0.4

GDF-7	Gdf7	U08339	BALB/c putative growth factor GDF7 (Gdf7) gene	TGF-beta superfamily	2.4 × 10–4	0.5	0.7–0.3

EBF	Ebf	NM_007897	early B-cell factor	Signal transduction	3.7 × 10–4	0.5	0.7–0.4

CD27/TNFRSF7	Tnfrsf7	L24495	CD27 antigen	TNF superfamily	6.4 × 10–4	0.6	0.8–0.4

SLIT-3	Slit3	AF088902	SLIT1 protein	Developmental factor	9.2 × 10–4	0.7	0.8–0.5

CX3CL1	Scyd1	NM_009142	small inducible cytokine subfamily D, 1	Chemokine	1.2 × 10–3	0.4	0.7–0.2

SMAD1	Madh1	NM_008539	MAD homolog 1 (Drosophila)	Signal transduction	1.3 × 10–3	0.6	0.8–0.5

A1	Bcl2a1a	L16462	hemopoietic-specific early response protein	Apoptosis related	1.5 × 10–3	0.6	0.8–0.4


Features$	Starter Group	Experimental Group	P Value

P1 max	0.080 ± 0.080	0.044 ± 0.044	0.011 *

P1 mean	0.050 ± 0.049	0.030 ± 0.030	0.017 *


Organization	Country	Title	Year

National Institute of Health Care and Excellence	United Kingdom	Recognition, referral, diagnosis, and management of adults with autism	2012

Australian Psychological Association	Australia	Clinical Assessment Resource: An overview of best practice tools and approaches to conducting biopsychosocial and developmental assessment of child, young people, and adults with a disability who display behaviors of concern	2011

Canadian Association of Occupational Therapists (CAOT)	Canada	Position Statement on Autism Spectrum Disorders and Occupational Therapy	2015

American Occupational Therapy Association (AOTA)	United States	Scope of Occupational Therapy Services for Individuals with ASD across the Life Course	2015

College of Occupational Therapy	United Kingdom	Occupational Therapy and Learning Disabilities	2012

Organization	Country	Title	Year

Canadian Association of Occupational Therapists (CAOT)	Canada	Position Statement on Autism Spectrum Disorders and Occupational Therapy	2015

American Occupational Therapy Association (AOTA)	United States	Scope of Occupational Therapy Services for Individuals with ASD across the Life Course	2015

College of Occupational Therapy	United Kingdom	Occupational Therapy and Learning Disabilities	2012


Coefficients of variation (CVs)	Children groups	ANOVA

	Spastic CP (n =10)	TD (n =10)	F1,18	p value	Effect size d

Utterance duration

 Mono-syllable task	17.87 ± 11.87	5.23 ± 2.33	10.923	0.004*	0.615

 Poly-syllable task	24.30 ± 17.90	7.57 ± 4.11	8.299	0.010	0.562

Peak vertical oral opening displacement

 Mono-syllable task	24.34 ± 13.53	34.14 ± 26.16	1.108	0.307	0.241

 Poly-syllable task	18.30 ± 15.82	29.42 ± 20.20	1.880	0.187	0.308

Peak vertical oral opening velocity

 Mono-syllable task	17.21 ± 14.97	24.69 ± 13.50	1.376	0.256	0.266

 Poly-syllable task	15.63 ± 17.09	15.16 ± 18.78	0.003	0.954	0.014


	Blastn (WGS An. gambiae)	Blastx (Nr)	Blastn (Nr)	Blastn (dbEST)	Unannotated	Total

3 Positive Controls	No Significant Hit	3				3

403 Unique Transcripts	403	240	8	112	43	403

Early Genes	144	77	2	45	20	144

Middle Genes	130	78	6	36	10	130

Late Genes	139	93	2	31	13	139

Total	413	248	10	112	43	413

	Blastn (WGS An. gambiae)

3 Positive Controls	No Significant Hit

403 Unique Transcripts	403

Early Genes	144

Middle Genes	130

Late Genes	139

Total	413


Study	Bacterial strain	Preparation	Patient population	Intervention	Results

 	 	 	Cell or animal type

In vitro experiments

 Strunk et al.,78 2012	SE 1457	Heat-killed	GA<30wk, 31-33 wk, 37-41 wk	6 h	IL-1β, IL-6, IL-8, TNF-α↑with GA

 	 	108cfu/ml	Cord & adult peripheral MNCs	 	Adult level TLR2 expression & phagocytosis

 Mohamed et al.,79 2007	SE PT 9657	Heat-killed	Healthy term infants	4 h	IL-1β, IL-6, IL-8, TNF-α↑with time

 	 	103cfu/ml	Cord & adult peripheral WBC	 	Pro-inflammatory effect: SE <E.coli & GBS

 Tatad et al.,80 2008	Clinical isolate	Heat-killed	Healthy term & preterm infants	 18 h	IL-6, IL-8, IL-10, IL-12↑ similar to adult

 	 	104cfu/ml	Cord & adult peripheral WBC	 	Inflammatory response: preterm > term

 Härtel et al.,81 2007	ATCC 12228	Live bacteria	Term & preterm infants	24 h	IL-6, TNF-α↑with GA

 	Strain 94B080	1cfu:1 WBC &	Neonatal peripheral WBC	 	Pro-inflammatory effect: BF+ strain<BF- strain

 	Strain 94B575	10 cfu:1 WBC	 	 	IL-10, TGF-β expression independent of GA

 Peoples et al.,82 2009	Clinical isolate	Heat-killed	Healthy term & preterm infants	18 h	IL-6, IL-10↑> adult

 	 	104 cfu/ml	Cord & adult peripheral WBC	 	IL-8, IL-12, INF-NK, INF-T↑ similar to adult

 	 	 	 	 	Inflammatory response: preterm=term

 Haase et al.,83 2011	ATCC 12228	Live bacteria	Healthy term & preterm infants	1 h	TNF-α, IL-6, IL-8↑

 	Strain 94B080	1cfu:1 WBC	Cord WBC	 	Pro-inflammatory effect: BF+ strain>BF- strain

 	Strain 94B575

 Björkqvist et al.,77 2004	Clinical isolate	Live bacteria	Healthy term & preterm infants	30 min	Oxidative burst intensity: preterm < term

 	 	10 cfu:1 PMNL	Neonatal peripheral PMNLs	 	SE similar to GBS

 Ivarsson et al.,104 2013	Clinical isolate	Live bacteria	Vascular endothelial cells	18 h	IL-8, ICAM-1 ↑

 	 	104cfu/ml	Small airway epithelial cells	 	Pro-inflammatory effect: SE > SA

 Hussain et al.,105 2013	Strain 94B080	Live bacteria	Bronchial epithelial cells	36 h	TNF-α, IL-6, IL-8 and iNOS↑ with time

 	 	104cfu/ml	 	 	Expression of ENaC and CFTR↑

In vivo experiments

 Kronforst et al.,87 2012	SE 1457	Live bacteria	C57BL/6 WT mice	48 h	At 2 h:

 	 	up to 2×109 cfu/ml	< 24 h old	 	IL-1β, IL-6, TNF-α, TLR2↑ with inoculum

 	 	 	 	 	At 24 h & 48 h:

 	 	 	 	 	Inoculum-dependent neonatal weight loss

 Bi et al.,86 2015	SE 1457	Live bacteria	C57BL/6J WT mice	72 h	At 6 h:

 	 	1×108cfu/ml	< 24 h old	 	IL-6, CCL2, CXCL1, IL-12↑ in blood & brain

 	 	 	 	 	Caspase-3 & TLR2 mRNA ↑ in the brain

 	 	 	 	 	At 24 h:

 	 	 	 	 	PMNLs↑ in blood & cerebral spinal fluid

 	 	 	 	 	White and grey matter impairment


Lymph nodes (median)	Chemotherapy eligibility (yes/no)

Positive

1 (0–3)	27/19

4 (1–11)	23/22

8 (2–26)	27/18

4 (0–26)	77/59


Drug’s name	Dose	Comments

Vasodilator drugs (hypotensives)

Propofol	2 - 2.5 mg/kg load, 25 - 75 μg/kg/min maintain	Local irritation, propofol infusion syndrome

Remifentanil	1 μg/kg load, 0.05 μg/kg/min maintain	Respiratory depression, hyperalgesia, vomiting

Dexmetedomidine	1 mg/kg load, 0.7 mg/kg/h maintain	Sedative effects

Nitroprusside	1 - 2 μg/kg/min	Severe hypotension, cyanide toxicity

Nitroglycerine	25 - 250 μg/min	Reflex tachycardia, methemoglobinemia

Nicardipine	5 mg/h	Braycardia, severe hypotension, cardiac blocks

Esmolol	5 - 10 mg/3 - 5 min bolus	AV block, bronchial hyperactivity

Labetalol	5 - 10 mg bolus

Urapidil	10 - 15 mg/h	Severe hypotension

Clonidine	0.1 - 1.2 mg	Rebound hypertension, dry mouth

Magnesium sulfate	1 - 8 mg load, 1 - 4 mg/h maintain	Potentiates muscle relaxants

Vasoconstrictor drugs (hypertensives)

Epinephrine	1 - 20 μg/min	Tachycardia

Norepinephrine	1 - 30 μg/min	Reflective bradycardia

Dopamine	5 - 10 μg/min	Tachycardia, arrhythmias

Phenilephrine	10 - 100 μg/min	Reflective bradycardia

Vasopressin	0.1 - 0.4 units/min	Myocardial infarction

Ephedrine	5 - 10 mg	None

Drug’s name

Vasodilator drugs (hypotensives)

Propofol

Remifentanil

Dexmetedomidine

Nitroprusside

Nitroglycerine

Nicardipine

Esmolol

Labetalol

Urapidil

Clonidine

Magnesium sulfate

Vasoconstrictor drugs (hypertensives)

Epinephrine

Norepinephrine

Dopamine

Phenilephrine

Vasopressin

Ephedrine

Dose	Comments

2 - 2.5 mg/kg load, 25 - 75 μg/kg/min maintain	Local irritation, propofol infusion syndrome

1 μg/kg load, 0.05 μg/kg/min maintain	Respiratory depression, hyperalgesia, vomiting

1 mg/kg load, 0.7 mg/kg/h maintain	Sedative effects

1 - 2 μg/kg/min	Severe hypotension, cyanide toxicity

25 - 250 μg/min	Reflex tachycardia, methemoglobinemia

5 mg/h	Braycardia, severe hypotension, cardiac blocks

5 - 10 mg/3 - 5 min bolus	AV block, bronchial hyperactivity

5 - 10 mg bolus

10 - 15 mg/h	Severe hypotension

0.1 - 1.2 mg	Rebound hypertension, dry mouth

1 - 8 mg load, 1 - 4 mg/h maintain	Potentiates muscle relaxants

1 - 20 μg/min	Tachycardia

1 - 30 μg/min	Reflective bradycardia

5 - 10 μg/min	Tachycardia, arrhythmias

10 - 100 μg/min	Reflective bradycardia

0.1 - 0.4 units/min	Myocardial infarction

5 - 10 mg	None


Mean (SD)	Non-atopic asthma n = 37	Atopic asthma n = 137	p value


Intervention	At Risk Target Population	Numbers at Risk Reached	% of Identified at Risk Reached by the RED Strategy	General Target Population in RED Catchment Areas	% of Additional Population Reached through the RED Strategy

Additional immunized children	489	477	97.55	3126 (children 1-15)	15% of the target children for immunization

Additional registered populations at Family Group Practices clinics	2598	2485	95.65	8708(Total Population in RED Area)	28.5% of total registered population at the family clinics

Additional ANC care contacts	515	508	98.64	5616(Total ANC Contacts in RED Area)	9% of all ANC Contacts

Additional family planning contacts	1047	1047	100.00	96560(Total Family Planning Contacts in RED Area)	1.08% of all family planning contacts

Additional emergency food provision	Not yet fully assessed	515	Not yet fully assessed	8708(Total Population in RED Area)	5.9% of Target population


Characteristic	Training set (n = 142)	Validation set (n = 112)

Patients	B4GALT1 expression	Patients	B4GALT1 expression

NO.	%	Low	High	P	NO.	%	Low	High	P

Age, years					0.614					0.763

Mean ± SD	62.4 ± 10.8		61.8 ± 10.9	62.7 ± 10.8		61.5 ± 8.7		61.8 ± 9.7	61.3 ± 7.6


Composition	CAS	RP-A	RP-E

Moisture	9.7	9.8	10.9

Protein	87.3	86.4	79.6

Carbohydrate	0.2	0.9	2.5

Lipids	0.5	0.8	0.8

Ash	1.7	1.0	1.5

Dietary fiber	0.6	1.1	4.7

Composition	CAS	RP-A

Moisture	9.7	9.8

Protein	87.3	86.4

Carbohydrate	0.2	0.9

Lipids	0.5	0.8

Ash	1.7	1.0

Dietary fiber	0.6	1.1


Design	Intervention	Country	Focus	Sample	Sample size(n)	Duration	Reference

Cluster blind RCT	Electronic decision support system	USA	GP	T1D, T2D	639	21 months	[15]

Cluster RCT	Diabetes register	UK	GP	T2D	3, 608	15 months	[16]

Cluster RCT	Diabetes register	USA	GP	T2D	7, 101	12 months	[17]

Cluster RCT	Electronic telemedicine	USA	Patient	T2D	1, 665	12 months	[18]

Cluster RCT	Electronic telemedicine	USA	GP	T2D	1, 665	12 months	[19]

Cluster RCT	Electronic self-management system	USA	Patient	T2D	886	12 months	[20]

RCT	Electronic self-management system	USA	Patient	T1D, T2D	122	6 months	[21]

RCT	Electronic self-management system	USA	Patient	T1D, T2D	104	12 months	[22]

RCT	Electronic self-management system	USA	Patient	T1D, T2D	62	6 months	[23]

Nonrandomised cluster control trial	Electronic management system	USA	GP	T1D, T2D	6, 646	24 months	[24]

Nonrandomised control trial	Diabetes register	USA	GP	T1D, T2D	898	20 months	[25]

Nonrandomised control trial	Personal Digital Assistant (PDA) based electronic management system	USA	GP	T2D	173	16 months	[26]

Nonrandomised control trial	Diabetes register	USA	GP	T1D, T2D	661	2 years	[27]

Nonrandomised control trial	Electronic decision support system	USA	GP	T1D, T2D	16	6 months	[28]

Single sample before and after design	Diabetes register	USA	GP	T1D, T2D	62	3 years	[29]

Single sample before and after design	Diabetes register	Korea	GP	T1D, T2D	185	3 months	[30]

Design	Intervention	Country

Cluster blind RCT	Electronic decision support system	USA

Cluster RCT	Diabetes register	UK

Cluster RCT	Diabetes register	USA

Cluster RCT	Electronic telemedicine	USA

Cluster RCT	Electronic telemedicine	USA

Cluster RCT	Electronic self-management system	USA

RCT	Electronic self-management system	USA

RCT	Electronic self-management system	USA

RCT	Electronic self-management system	USA

Nonrandomised cluster control trial	Electronic management system	USA

Nonrandomised control trial	Diabetes register	USA

Nonrandomised control trial	Personal Digital Assistant (PDA) based electronic management system	USA

Nonrandomised control trial	Diabetes register	USA

Nonrandomised control trial	Electronic decision support system	USA

Single sample before and after design	Diabetes register	USA

Single sample before and after design	Diabetes register	Korea

Focus	Sample	Sample size(n)	Duration	Reference

GP	T1D, T2D	639	21 months	[15]

GP	T2D	3, 608	15 months	[16]

GP	T2D	7, 101	12 months	[17]

Patient	T2D	1, 665	12 months	[18]

GP	T2D	1, 665	12 months	[19]

Patient	T2D	886	12 months	[20]

Patient	T1D, T2D	122	6 months	[21]

Patient	T1D, T2D	104	12 months	[22]

Patient	T1D, T2D	62	6 months	[23]

GP	T1D, T2D	6, 646	24 months	[24]

GP	T1D, T2D	898	20 months	[25]

GP	T2D	173	16 months	[26]

GP	T1D, T2D	661	2 years	[27]

GP	T1D, T2D	16	6 months	[28]

GP	T1D, T2D	62	3 years	[29]

GP	T1D, T2D	185	3 months	[30]


 	Amplitude of extension reflex score < 2.5	Rotarod time on rod < 90 s	Symmetry of extension reflex score < 1	Stride length < 5 cm

hA30Pα-syn+/+	18.1 ± 0.2 months	19.3 ± 0.2 months	20.0 ± 0.2 months	20.7 ± 0.2 months

parkin+/-; hA30Pα-syn+/+	18.4 ± 0.2 months	20.2 ± 0.2 months	22.3 ± 0.2 months	23.0 ± 0.2 months

parkin-/-; hA30Pα-syn+/+	21.0 ± 0.2 months	23.2 ± 0.2 months	23.4 ± 0.2 months	> 24 months

	Amplitude of extension reflex score < 2.5	Rotarod time on rod < 90 s	Symmetry of extension reflex score < 1	Stride length < 5 cm

parkin+/-; hA30Pα-syn+/+	18.4 ± 0.2 months	20.2 ± 0.2 months	22.3 ± 0.2 months	23.0 ± 0.2 months

parkin-/-; hA30Pα-syn+/+	21.0 ± 0.2 months	23.2 ± 0.2 months	23.4 ± 0.2 months	> 24 months


	%

	Arthritis	Stroke	Angina	Diabetes	Lung disease	Asthma	Depression	Cataracts

No hypertension	18.30	1.13	5.85	4.55	3.33	3.16	3.76	2.78

Hypertension diagnosed and measured	35.61	8.91	6.25	21.44	4.02	7.35	3.63	8.92

Hypertension measured but not diagnosed	18.83	2.24	3.43	4.32	1.54	3.05	1.40	1.18

Normal blood pressure but diagnosed with hypertension	38.90	3.91	12.32	15.65	7.72	14.43	7.55	12.56

	%

	Arthritis	Stroke	Angina	Diabetes	Lung disease	Asthma	Depression	Cataracts

Hypertension diagnosed and measured	35.61	8.91	6.25	21.44	4.02	7.35	3.63	8.92

Hypertension measured but not diagnosed	18.83	2.24	3.43	4.32	1.54	3.05	1.40	1.18

Normal blood pressure but diagnosed with hypertension	38.90	3.91	12.32	15.65	7.72	14.43	7.55	12.56


Outcome	Impact of Statins on rate of events modeled using Cox Proportional Hazards (HR, 95% CI) (Statin versus No Statin)	Impact of Statins on number of events, modeled using Generalized Linear Models (RR, 95% CI) (Statin versus No Statin)

All-cause re-hospitalizations

Modeled without propensity score	0.84 (0.78-0.90)	0.97 (0.90-1.04)

Modeled with propensity score	0.98 (0.91-1.06)	1.04 (0.97-1.12)

CVD re-hospitalizations

Modeled without propensity score	0.98 (0.90-1.07)	0.90 (0.86-1.12)

Modeled with propensity score	1.11 (1.02-1.22)	1.03 (0.92-1.16)

All physician visits	N/A

Modeled without propensity score		0.84 (0.79-0.88)

Modeled with propensity score		0.97 (0.92-1.02)

CVD-related physician visits	N/A

Modeled without propensity score		1.18 (1.09-1.29)

Modeled with propensity score		1.34 (1.23-1.46)

Coronary Revascularizations		N/A

Modeled without propensity score	1.55 (1.30-1.84)

Modeled with propensity score	1.15 (0.97-1.36)

Mortality		N/A

Modeled without propensity score	0.41 (0.35-0.49)

Modeled with propensity score	0.74 (0.63-0.88)

Outcome	Impact of Statins on rate of events modeled using Cox Proportional Hazards (HR, 95% CI) (Statin versus No Statin)	Impact of Statins on number of events, modeled using Generalized Linear Models (RR, 95% CI) (Statin versus No Statin)

Modeled without propensity score	0.41 (0.35-0.49)

Modeled with propensity score	0.74 (0.63-0.88)


Variables	Category	TB status	p value

No (N = 520)	Yes (N = 130)

Age in year, mean ± std. error of mean	33.6 ± 0.4	33.4 ± 0.8	0.850

Gender	Male, N (%)	165 (31.7)	56 (43.1)	0.017

Female, N (%)	355 (68.3)	74 (56.9)


Variable	Mean (SD)	P-value

Material	CEM cement	68* (28)	0.92

MTA	67 (39)

Subgroups	AP+GP	55 (28)	0.005

AP+TO	67 (14)

Obturation with AP material	56 (29)

Unfilled	96 (37)


	Komfo-Anokye (disclosure intervention)	Korle-Bu (usual care)		Total

	N = 131(%)	N = 167(%)	P value	N = 298(%)


Author	GA at diagnosis (weeks)	Treatment	Complications	Follow-up (months)	Outcome

Benedetto et al.	9	Endoscopy with HCPs	no	1	Normal

Chen et al.	31	Endoscopy with HCPs	HELLP syndrome	2	Normal


GBR	Auto only	Auto + xeno	Xeno only	Syn only	Total

No	40	44	79	17	180

%	22.2	24.4	43.9	9.4	100.0

Auto + xeno	Xeno only	Syn only	Total

44	79	17	180

24.4	43.9	9.4	100.0


Variable	Biliary acute Pancreatitis (n = 425)	Hypertriglyceridemia acute Pancreatitis (n = 305)	P value

Hospital mortality, no.	36(8.5%)	24(7.9%)	0.787

Need of surgery, no.	39(9.2%)	33(10.8%)	0.529

ICU admission	260(61.2%)	186(61.0%)	1

Length of ICU stay, days	4(2,12)	4(2,10.5)	0.975

Length of hospital stay, days	9(4,22.5)	9(5,23)	0.58

Cost, Thousand CHY	48.7(22.8157.8)	51.0(27.9134.6)	0.623

Variable	Biliary acute Pancreatitis (n = 425)	Hypertriglyceridemia acute Pancreatitis (n = 305)	P value

Length of hospital stay, days	9(4,22.5)	9(5,23)	0.58

Cost, Thousand CHY	48.7(22.8157.8)	51.0(27.9134.6)	0.623


Drug	Disease/disturbance	Side effect

Cefradine	Urinary tract infection	Hypersensitivity, elevated liver enzyme, diarrhea

Nitroxoline	Urinary tract infection	Gastrointestinal intolerance, urine coloration

Sulfonamide	Urinary tract infection	Hypersensitivity, folic acid deficiency, hematological abnormality

Levofloxacin	Urinary tract infection	Diarrhea, tendinitis, seizure neuropathy, elevated liver enzyme

Atenolol	Hypertension	Bradycardia, cough, Raynaud's syndrome

Amlodipine	Hypertension	Flush, tachycardia, edema

Solantin	Thromboembolism	Dizziness, abdomen distress, angina, headache

Ursodeoxycholic acid	Liver cirrhosis	Gastrointestinal disturbance

Atorvastatin	Hyperlipidemia	Gastrointestinal disturbance, elevated liver enzyme, myopathy, neuropathy

Chinese herb drugs	Multiple somatic complaints	Unknown


Patient study code	Pre-study dopamine agonist	Trial arm	First IMP	Daily dose (mg)	Number of days on IMP	Second IMP	Daily dose (mg)	Number of days on IMP

PD1	RPR	1	PPX	2.1	3	RPRa, b	8	134

PD2	RPR	1	PPX	2.62	58	RPR	10	48

PD3	RPR	2	RPR	6	51	PPX	1.57	58

PD4	RPR	2	RPR	4	40	PPX	1.05	55

PD5	Consented but then withdrew before taking first IMP

PD6	PPX	1	PPX	2.1	64	RPR	8	52

PD7	PPX	2	RPR	10	13	PPXa, b	2.62	97

PD8	RPR	2	RPR	12	54	PPX	3.15	62

PD9	PPX	1	PPX	1.57	62	RPR	6	56

PD10	RPR	1	PPX	2.1	53	RPR	8	68

PD11	PPX	1	PPX	1.05	48	RPRb	4	30

PD12	PPX	2	RPR	10	52	PPX	2.62	56

PD13	Consented but then withdrew before taking first IMP

PD14	PPX	1	PPX	0.52	52	RPR	2	37

PD15	Consented but then withdrew before taking first IMP

PD16	PPX	1	PPX	1.57	63	RPR	6	55

PD17	PPX	2	RPR	6	60	PPX	1.57	37

PD18	PPX	2	RPR	6	3	Withdrew from IMP and study

PD19	RPR	1	PPX	2.1	55	RPR	8	84

PD20	PPX	2	RPR	8	66	PPX	2.1	41

PD21	PPX	1	PPX	3.15	100	RPRb	12	7

PD22	RPR	2	RPR	6	55	PPX	1.57	48

PD23	PPX	2	RPR	8	5	Withdrew from IMP and study

PD24	RPR	2	RPR	6	58	PPX	1.57	37

PD25	RPR	2	RPR	2	68	PPX	0.52	62

Patient study code	Pre-study dopamine agonist	Trial arm	First IMP	Daily dose (mg)	Number of days on IMP	Second IMP	Daily dose (mg)	Number of days on IMP

PD23	PPX	2	RPR	8	5	Withdrew from IMP and study

PD24	RPR	2	RPR	6	58	PPX	1.57	37

PD25	RPR	2	RPR	2	68	PPX	0.52	62


Parental feeding practices	Family breakfast frequency	Family dinner frequency	Family supper frequency

Monitoring	.11*	.04	.02

Child control	-.09**	-.11*	-.03

Encourage balance and variety	.06	.08**	.04

Environment	.13*	.09**	.12*

Involvement	.01	-.00	.02

Pressure to eat	.08**	.00	.01

Restriction for weight	-.01	-.04	-.02

Food as reward	-.02	-.09**	-.00

Restriction for health	-.05	-.06	-.05

Teaching nutrition	.10*	.06	.09**

Modeling	.11*	.06	.08**

Emotion regulation	-.02	-.08**	.01

Parental feeding practices

Monitoring

Child control

Encourage balance and variety

Environment

Involvement

Pressure to eat

Restriction for weight

Food as reward

Restriction for health

Teaching nutrition

Modeling

Emotion regulation


Variables

Female/male (n/n)

Age (years)

Duration of diabetes (years)

Plasma glucose (mmol/L)

HbA1c (%)

Arterial pH

HCO3 (mmol/L)

Alanine aminotransferase (U/L)

Aspartate aminotransferase (U/L)

γ-glutamyl transpeptidase (U/L)

Total bilirubin (μmol/L)

Direct bilirubin (μmol/L)

Total protein (g/L)

Albumin (g/L)

Globulin (g/L)

Prealbumin (mg/dL)

Serum creatinine (μmol/L)

eGFR (mL/min per 1.73 m2)

Uric acid (μmol/L)


Target gene symbol	miRNAs

GRASP	hsa-miR-320b

TSPYL5	hsa-miR-193a-3p

	hsa-let-7g

	hsa-let-7a

	hsa-let-7e

	hsa-let-7c

	hsa-let-7b

	hsa-miR-320b

	hsa-miR-27b


Diagnoses	Patient count	% of Total

Pre-Index Period

Total Unique Patients in the Population	5,490

Patients with ≥ 1 Pertussis-like event	3,140	57

Acute Respiratory:	2,857	52

 COUGH	1,350	25

 UPPER RESPIRATORY TRACT INFECTION	1,004	18

 ACUTE BRONCHITIS	938	17

 ASTHMA	449	8

 ALLERGY	413	8

 LOWER RESPIRATORY TRACT INFECTION	387	7

 OTHER PNEUMONIA	313	6

Other :	1,798	33

 HYPERTENSION	579	11

 SHORTNESS OF BREATH	368	7

 HIGH CHOLESTEROL	316	6

 GERD	290	5

 CHEST PAIN	266	5

 COPD AND OTHER ALLIED CONDITIONS	229	4

 DIABETES	224	4

 LUMBAR STRAIN OR BACK PAIN	171	3

Post-Index Period

Total Unique Patients in the Population	5,490	100

Acute Respiratory:	5,053	92

 WHOOPING COUGH-UNSPECIFIED ORGANISM	2,224	41

 COUGH	2,222	40

 UPPER RESPIRATORY TRACT INFECTION	770	14

 ACUTE BRONCHITIS	694	13

 WHOOPING COUGH-BORDETELLA PERTUSSIS	605	11

 ASTHMA	551	10

 OTHER PNEUMONIA	468	9

 ALLERGY	404	7

 LOWER RESPIRATORY TRACT INFECTION	359	7

 PNEUMONIA IN WHOOPING COUGH	237	4

Other:	2,309	42

 HYPERTENSION	851	16

 HIGH CHOLESTEROL	495	9

 SHORTNESS OF BREATH	445	8

 DIABETES	421	8

 GERD	421	8

 COPD AND OTHER ALLIED CONDITIONS	388	7

 CHEST PAIN	300	5

Diagnoses

Pre-Index Period

Total Unique Patients in the Population

Patients with ≥ 1 Pertussis-like event

Acute Respiratory:

COUGH

UPPER RESPIRATORY TRACT INFECTION

ACUTE BRONCHITIS

ASTHMA

ALLERGY

LOWER RESPIRATORY TRACT INFECTION

OTHER PNEUMONIA

Other :

HYPERTENSION

SHORTNESS OF BREATH

HIGH CHOLESTEROL

GERD

CHEST PAIN

COPD AND OTHER ALLIED CONDITIONS

DIABETES

LUMBAR STRAIN OR BACK PAIN

Post-Index Period

Total Unique Patients in the Population

Acute Respiratory:

WHOOPING COUGH-UNSPECIFIED ORGANISM

COUGH

UPPER RESPIRATORY TRACT INFECTION

ACUTE BRONCHITIS

WHOOPING COUGH-BORDETELLA PERTUSSIS

ASTHMA

OTHER PNEUMONIA

ALLERGY

LOWER RESPIRATORY TRACT INFECTION

PNEUMONIA IN WHOOPING COUGH

Other:

HYPERTENSION

HIGH CHOLESTEROL

SHORTNESS OF BREATH

DIABETES

GERD

COPD AND OTHER ALLIED CONDITIONS

CHEST PAIN


Item	Experiment A [8]	Experiment B

Study design	Design: parallel crossover Diets: control (CON) and treatment (TRMT)Duration: 22 d with glucose kinetics assessed on day 19 of study 	Design: parallel crossoverDiets: control (CON) and treatment (TRMT)Duration: 63 d with glucose kinetics assessed on day 35 of study

Study population	A total of 6 neutered male Labrador Retrievers, 3-black-coated (3.9 yr; 27.3 kg) and 3-chocolate-coated (6.8 yr; 35.0 kg)	A total of 12 black Labrador Retrievers, 5 spayed females and 7 neutered males (27.0 ± 0.6 kg; 4.9 ± 0.2 yr of age)

Key details of glucose kinetics experiment	Isotope: U-13C-glucosePrime: 77.8 μmol/kgConstant: 0.136 μmol/min·kgFasting collections (18 h since last meal): 6 blood samples were taken at 60, 85, 110, 135, 160, and 185 min followed by 4 breath samples taken at 220, 245, 270, and 295 min after isotope infusion (start of isotope infused considered time 0) Postprandial collections: total food ration of 14 g/kg divided into 15 equal sized meals fed in 25 min intervals; 6 blood samples were taken at 60, 85, 110, 135, 160, and 185 min followed by 4 breath samples taken at 220, 245, 270, 295, 320, and 345 min after initial meal	Isotope: U-13C-glucosePrime: 8.1 μmol/kgConstant: 0.136 μmol/min·kgFasting collections (18 h since last meal): 6 fasting blood samples were taken at 90, 105, 120, 135, 150, and 165 min followed by 6 breath samples taken at 180, 205, 230, 255, 280, and 305 min after isotope infusion (start of isotope infused considered time 0)Postprandial collections: total food ration of 23 g/kg divided into 14 equal sized meals fed in 25 min intervals; 6 fasting blood samples were taken at 90, 105, 120, 135, 150, and 165 min followed by 6 breath samples taken at 180, 205, 230, 255, 280, and 305 min after initial meal.

Item	Experiment A [8]	Experiment B

Study population	A total of 6 neutered male Labrador Retrievers, 3-black-coated (3.9 yr; 27.3 kg) and 3-chocolate-coated (6.8 yr; 35.0 kg)	A total of 12 black Labrador Retrievers, 5 spayed females and 7 neutered males (27.0 ± 0.6 kg; 4.9 ± 0.2 yr of age)

Key details of glucose kinetics experiment	Isotope: U-13C-glucosePrime: 77.8 μmol/kgConstant: 0.136 μmol/min·kgFasting collections (18 h since last meal): 6 blood samples were taken at 60, 85, 110, 135, 160, and 185 min followed by 4 breath samples taken at 220, 245, 270, and 295 min after isotope infusion (start of isotope infused considered time 0) Postprandial collections: total food ration of 14 g/kg divided into 15 equal sized meals fed in 25 min intervals; 6 blood samples were taken at 60, 85, 110, 135, 160, and 185 min followed by 4 breath samples taken at 220, 245, 270, 295, 320, and 345 min after initial meal	Isotope: U-13C-glucosePrime: 8.1 μmol/kgConstant: 0.136 μmol/min·kgFasting collections (18 h since last meal): 6 fasting blood samples were taken at 90, 105, 120, 135, 150, and 165 min followed by 6 breath samples taken at 180, 205, 230, 255, 280, and 305 min after isotope infusion (start of isotope infused considered time 0)Postprandial collections: total food ration of 23 g/kg divided into 14 equal sized meals fed in 25 min intervals; 6 fasting blood samples were taken at 90, 105, 120, 135, 150, and 165 min followed by 6 breath samples taken at 180, 205, 230, 255, 280, and 305 min after initial meal.


Use of allopirunol, n

Use of febuxostat, n

Use of benzbromarone, n

Use of combination urate-lowering therapies, n

Lifestyle intervention only, n


Parameters	N = 506

Age in years, mean (SD)	23.8 (3.4)

Age categories

<20 yr, n (%)	10 (1.9)

20-29 yr, n (%)	454 (89.9)

≥30 yr, n (%)	41 (8.1)

Residence

Urban, n (%)	148 (29.2)

Rural, n (%)	359 (70.8)

Education

No schooling, n (%)	161 (31.8)

Primary, n (%)	136 (26.8)

Secondary, n (%)	173 (34.2)

Higher, n (%)	36 (7.1)

SES1 rank (quintiles) n (%)

1 – Poorest	117 (23.1)

2	107 (21.2)

3	112 (22.1)

4	85 (16.8)

5	85 (16.8)

Gravidity

Primigravidae, n (%)	216 (42.7)

Secundigravidae, n (%)	162 (32.0)

Gravidae-3, n (%)	73 (14.4)

Gravidae-4, n (%)	34 (6.7)

Multigravidae (≥5)2 n (%)	21 (4.2)

Used bednet previous night, n (%)	89 (17.8)

ITN (any), n (%)	1 (0.2)

Used any drug to prevent malaria, n (%)	4 (0.8)

Reported using haematinics, n (%)	427 (84.7)

Morbidity and Outcomes

Reported fever previous week, n (%)	82 (16.2)

Used antimalarial for fever, n (%)	10 (1.9)

Maternal fever at delivery3, n (%)	35 (6.9)

Birth weight± (g), mean (SD)	2621 (450)

Birth weight <2500 g, n (%)	176 (37.1)

Baby’s gestational age in weeks4, mean, (SD)	37.2 (1.3)

Preterm babies <37 weeks), n (%)	95 (20.0)

Stillbirths≠, n (%)	22 (4.4)

Stillbirths in uninfected women, n (%)	18 (3.6)

Maternal Hb (g/dL), mean (SD)	10.5 (2.2)

Parameters	N = 506

	85 (16.8)

5	85 (16.8)

Gravidity

Primigravidae, n (%)	216 (42.7)

Secundigravidae, n (%)	162 (32.0)

Gravidae-3, n (%)	73 (14.4)

Gravidae-4, n (%)	34 (6.7)

Multigravidae (≥5)2 n (%)	21 (4.2)

Used bednet previous night, n (%)	89 (17.8)

ITN (any), n (%)	1 (0.2)

Used any drug to prevent malaria, n (%)	4 (0.8)

Reported using haematinics, n (%)	427 (84.7)

Morbidity and Outcomes

Reported fever previous week, n (%)	82 (16.2)

Used antimalarial for fever, n (%)	10 (1.9)

Maternal fever at delivery3, n (%)	35 (6.9)

Birth weight± (g), mean (SD)	2621 (450)

Birth weight <2500 g, n (%)	176 (37.1)

Baby’s gestational age in weeks4, mean, (SD)	37.2 (1.3)

Preterm babies <37 weeks), n (%)	95 (20.0)

Stillbirths≠, n (%)	22 (4.4)

Stillbirths in uninfected women, n (%)	18 (3.6)

Maternal Hb (g/dL), mean (SD)	10.5 (2.2)


Toxicity	Overall incidence, no. (%)	Grade 1 and 2, no. (%)	Grade 3 and 4, no. (%)

Hyperglycemia	19 (79)	19 (79)

Fatigue	19 (79)	18 (75)	1 (4)

Thrombocytopenia	12 (50)	12 (50)

Headache	11 (46)	10 (43)	1 (4)

Nausea	10 (42)	9 (38)	1 (4)

Leukopenia	9 (38)	9 (38)

ALT elevations	8 (33)	8 (33)

AST elevations	7 (29)	7 (29)

Bilirubin elevations	5 (21)	5 (21)

Neutropenia	5 (21)	5 (21)

Anemia	5 (21)	4 (17)	1 (4)

Seizures	5 (21)	4 (17)	1 (4)

Vomiting	5 (21)	4 (17)	1 (4)

Thyroid toxicity	4 (17)	4 (17)

Diarrhea	4 (17)	4 (17)

Myalgias/Arthralgias	3 (13)	3 (13)

Rash	2 (8)	2 (8)

Pyrexia	2 (8)	2 (8)

Lipase	1 (4)	1 (4)

Amylase	1 (4)	1 (4)

Mucositis	1 (4)	1 (4)

Toxicity	Overall incidence, no. (%)	Grade 1 and 2, no. (%)	Grade 3 and 4, no. (%)

Amylase	1 (4)	1 (4)

Mucositis	1 (4)	1 (4)


Characteristics	Category

Age (years)	<10

11–14

>14

Education	Preschool

Pupil

Other

Perpetrator	Father

Stepfather

Stepbrother

Cousin

Grandfather

Other relative

Familiar

Stranger

Escorter	Alone

Mother

Parents

Other relative

Familiar

Paramedical officer

Police


Age	87 years

Symptoms	Nocturnal leg cramps of moderate intensity since years. Since three weeks intensity of symptoms increased despite the use of quinine for symptomatic relief

Medical history	myocardial infarction in 2002 with consecutive coronary artery bypass graft (CABG)arterial hypertensionchronic kidney disease IIIknee replacement left + right.

Medication	aspirin 100 mg 1-0-0bisoprolol 2,5 mg 1-0-0ramipril 5 mg 1-0-0simvastatin 40 mg 0-0-1vitamin D3 1000 IU 1-0-0torasemide 5 mg 1-0-0fentanyl patch 12,5 μg once every 3 days.Self-medication: quinine200 mg once daily

Age

Symptoms

Medical history

Medication

87 years

Nocturnal leg cramps of moderate intensity since years. Since three weeks intensity of symptoms increased despite the use of quinine for symptomatic relief

myocardial infarction in 2002 with consecutive coronary artery bypass graft (CABG)arterial hypertensionchronic kidney disease IIIknee replacement left + right.

aspirin 100 mg 1-0-0bisoprolol 2,5 mg 1-0-0ramipril 5 mg 1-0-0simvastatin 40 mg 0-0-1vitamin D3 1000 IU 1-0-0torasemide 5 mg 1-0-0fentanyl patch 12,5 μg once every 3 days.Self-medication: quinine200 mg once daily


Possible outcome in eradication studies	How does the outcome affect reservoir measures?

1. Preferential reduction in intact proviruses	Integrated HV DNA is likely to be unchanged. Proviral sequencing would likely detect a reduction in the fraction of replication-competent proviruses which could be combined with integration measures to determine the absolute reduction in intact proviruses

2. Preferential reduction in defective proviruses	Integrated HIV DNA would decrease, without reflecting a contraction in the size of the “true” reservoir. Proviral sequencing would likely capture the change in the fraction of defective proviruses

3. Decrease in both intact and defective proviruses	If intact and defective proviruses are targeted differently, a decrease in integrated HIV DNA would occur, but would not likely be proportional to the decrease in the number of intact proviruses. Proviral sequencing combined with integration measures would likely capture the changes in the reservoir size and character


Time point	N 	PD	F 	P value

Mean ± SD

Baseline 	25	61.04 ± 10.45	5.399 	0.00*

Second week 	25	66.60 ± 10.74

Fourth week 	25	69.64 ± 9.45

Sixth week 	25	71.40 ± 8.23

Time point	N	Mean ± SD	F	P value

Baseline	25	61.04 ± 10.45	5.399	0.00*

Second week	25	66.60 ± 10.74

Fourth week	25	69.64 ± 9.45

Sixth week	25	71.40 ± 8.23


Paper	Country	Time period of breast cancer deaths	Cases (n)	Screening exposure	Crude Ors (95% CI)	ORs adjusted for self-selection bias

Allgood et al. [15]	UK	1995-2004	284	Ever/Never attendance before (pseudo) diagnosis	0.35 (0.24-0.51)	0.52 (0.32-0.84)

Fielder et al. [16]	Wales	1998-2001	419	Ever/Never attendance before (pseudo) diagnosis	0.62 (0.47-0.82)	0.75 (0.49-1.14)

Gabe et al. [17]	Iceland	1990-2002	226	Ever/Never attendance before (pseudo) diagnosis	0.59 (0.41-0.84)	0.65 (0.39-1.09)

Paap et al. [18]	Netherlands	2004-2005	118	Screened at index invitation	0.30 (0.14-0.63)	0.24 (0.10-0.58)

Puliti et al. [19]	Italy	1988-2002	1750	Ever/Never attendance before (pseudo) diagnosis	0.46 (0.38-0.56)	0.55 (0.36-0.85)

Roder et al. [20]	Australia	2002-2005	491	Ever/Never attendance before (pseudo) diagnosis	0.59 (0.47-0.74)	0.70a


	n (%)	L1CAM expression n (%)	n (%)

Negative	≤ 20% of tumor cells	>20% of tumor cells		P value

Recurrence	9 (16)	14 (24)	34 (60)	57

No recurrence	24 (43)	19 (34)	13 (23)	56	< 0.0001


Class I (Positive)	Class II (Positive)

Cw10, B27, B57, B51, B61, B13, B44

B75, B55, Cw4, Cw12, B49, B38, Cw1


	Fully vaccinated, positive responsesan = 75n (%)	Non-vaccinated positive responsesan = 119n (%)	Fisher’s exact testp-value

Knowledge items

 HPV is a sexually transmitted infection	73 (97.3)	106 (89.8)	0.08

 Men and women can be carriers of HPV	74 (98.7)	108 (91.5)	0.05

 HPV vaccine protects against genital warts	58 (77.3)	86 (72.3)	0.50

 HPV vaccine protects against cervical cancer	72 (96.0)	104 (87.4)	0.07

 HPV vaccine protects against other cancers	36 (48.0)	56 (47.9)	1.00

 HPV vaccine is safe	71 (95.9)	102 (85.7)	0.03*

 HPV vaccine is effective	71 (95.9)	104 (87.4)	0.07

 HPV vaccine has few side effects	64 (85.3)	83 (70.3)	0.02*

 HPV vaccination leads to lasting immunity	49 (65.3)	58 (49.2)	0.04*

 HPV vaccine is recommended for girls and boys	68 (90.7)	83 (70.3)	<0.001*

Attitude items

 HPV vaccination may lead to risky sexual behavior	4 (5.3)	10 (8.4)	0.57

 I have enough information to be able to counsel about HPV vaccine	35 (46.7)	45 (38.1)	0.29

 I feel comfortable counseling about HPV vaccination	34 (45.3)	44 (37.3)	0.29

 I would recommend the HPV vaccine to friends and family	73 (97.3)	81 (69.2)	<0.001*

 HPV vaccine should be mandatory	53 (72.6)	44 (38.3)	<0.001*

	Fully vaccinated, positive responsesan = 75n (%)	Non-vaccinated positive responsesan = 119n (%)	Fisher’s exact testp-value

Knowledge items

HPV is a sexually transmitted infection	73 (97.3)	106 (89.8)	0.08

Men and wom	74 	108 (91.5	0.

	Fully vaccinated, positive responsesan = 75n (%)	Non-vaccinated positive responsesan = 119n (%)	Fisher’s exact testp-value

en can be carriers of HPV	(98.7)	)	05

HPV vaccine protects against genital warts	58 (77.3)	86 (72.3)	0.50

HPV vaccine protects against cervical cancer	72 (96.0)	104 (87.4)	0.07

HPV vaccine protects against other cancers	36 (48.0)	56 (47.9)	1.00

HPV vaccine is safe	71 (95.9)	102 (85.7)	0.03*

HPV vaccine is effective	71 (95.9)	104 (87.4)	0.07

HPV vaccine has few side effects	64 (85.3)	83 (70.3)	0.02*

HPV vaccination leads to lasting immunity	49 (65.3)	58 (49.2)	0.04*

HPV vaccine is recommended for girls and boys	68 (90.7)	83 (70.3)	<0.001*

Attitude items

HPV vaccination may lead to risky sexual behavior	4 (5.3)	10 (8.4)	0.57

I have enough information to be able to counsel about HPV vaccine	35 (46.7)	45 (38.1)	0.29

I feel comfortable counseling about HPV vaccination	34 (45.3)	44 (37.3)	0.29

I would recommend the HPV vaccine to friends and family	73 (97.3)	81 (69.2)	<0.001*

HPV vaccine should be mandatory	53 (72.6)	44 (38.3)	<0.001*


Gene	Sequence (5' to 3')

Abcc4

 - forward	TGCTTCCCAGACTCTGCACAAC

 - reverse	AAGCAAGTCGTCCATGTGTCCG

Akr1c9

 - forward	CAAGTGCCTTTGAATGCTGAGCC

 - reverse	ACACCCACTTCATGCCCAAGAC

AR

 - forward	AGAAAAAATCCCACATCCTGC

 - reverse	CATCATTTCAGGAAAGTCCACG

Dhcr24

 - forward	TGCTGAACTCCATTGGCTGGAC

 - reverse	TTGTGGGACGATGACTCGATGC

Facl3

 - forward	TCAGGCCAAGGCAAACTCCATTC

 - reverse	TGCCAAAGCAAACTGGAGGAGG

Gucy1a3

 - forward	AAGCTGAAGGCAACCTTGGAGC

 - reverse	TTTGTCCTTGCCAGAGCTGCTG


	Proteins with high IS	P-value

100 most abundant proteins with IS in L. interrogans	7	.0067

100 most abundant non-ribosomal proteins with IS in L. interrogans	9	.033

100 most abundant non-ribosomal proteins with IS in E. coli	6	.0013

100 most abundant non-ribosomal proteins with IS in E. coli	9	.033


Variables	Specificity (%)	Sensitivity (%)	PPV (%)	NPV (%)	AUC	YI	Best Cut-off	p


 	Children with ESRD

 	(n=92)

Age (years)	13.1 (0.7-19.1)

Male*	51 (55%)

Weight (kilograms)	37.8 (4.3-96.0)

BSA (m2)	1.2 (0.4-2.2)

Height (cm)	138 (61–184)

Duration of RRT (years)	1.8 (0.0-6.8)

Modality at time of Echocardiography*

-Hemodialysis	26 (28%)

-Peritoneal dialysis	24 (26%)

-Transplantation	42 (46%)

Age (years)

Male*

Weight (kilograms)

BSA (m2)

Height (cm)

Duration of RRT (years)

Modality at time of Echocardiography*

-Hemodialysis

-Peritoneal dialysis

-Transplantation


Totle SNP	Non coding SNP	Coding SNP	Synonymous	Nonsynonymous

12,518	8863(70.80 %)	3655(29.20 %)	3632	23

Totle SNP	Non coding SNP

12,518	8863(70.80 %)

Coding SNP	Synonymous	Nonsynonymous

3655(29.20 %)	3632	23


	Incidence before varicella vaccination (per 1000 population)	Reduction since varicella vaccination* (%)

USA	Uruguay	USA	Uruguay

<1 year	19.7	14.3	68–81	63–80

1–4 years	48.8	56.7	83–90	94–97

5–9 years	34.5	41.6	63–77	73–81

10–14 years	9.5	13.2	65–80	62–65

	Incidence before varicella vaccination (per 1000 population)	Reduction since varicella vaccination* (%)

USA	Uruguay	USA	Uruguay

5–9 years	34.5	41.6	63–77	73–81

10–14 years	9.5	13.2	65–80	62–65


First author	Year	Country	Racial/descent	Source of controls	Case	Control	Genotype distribution	Pfor HWEa	Genotying type

Case	Control

GG	GA	AA	GG	GA	AA

Catarino	2005	Portugal	Caucasian	Healthy base	143	103	35	64	44	9	55	39	0.091	PCR-RFLP

Jeon	2005	Korean	Asian	Hospital base	222	314	49	112	61	80	160	74	0.730	PCR-RFLP

Catarino	2008	Portugal	Caucasian	Hospital base	226	247	60	103	63	40	138	69	0.037	PCR-RFLP

Satinder	2008	India	Asian	Healthy base	150	150	33	64	53	30	65	55	0.184	PCR-RFLP

Thakur	2009	India	Asian	Hospital base	200	200	39	94	67	47	119	34	0.006	PCR-RFLP

Castro	2009	Sweden	Caucasian	Population base	952	1713	229	463	260	465	837	411	0.367	Multiplex PCR and hybridization

Ni	2011	China	Asian	Hospital base	300	312	48	160	92	70	137	105	0.051	PCR-RFLP

Warchoł	2011	Poland	Caucasian	Healthy base	129	288	35	65	29	116	123	49	0.100	PCR-RFLP

Wang	2012	China	Asian	Population base	327	411	86	180	61	92	203	116	0.859	PCR-RFLP

Djansugurova	2013	Kazakhstan	Caucasian	Healthy base	215	160	54	103	58	41	78	41	0.752	Direct sequencing


	ASD	TD

Head ROI

 Implicit mentalizing-action	4.64 (9.68)	2.32 (12.01)

 Implicit either-action	4.32 (8.00)	0.37 (11.08)

 Explicit mentalizing-non-mentalizinga	0.06 (18.05)	1.91 (13.13)

Poker chip ROI

 Implicit mentalizing-action	1.16 (6.15)	− 1.83 (8.76)

 Implicit either-action	2.36 (5.58)	2.12 (11.96)

 Explicit mentalizing-non-mentalizinga	4.12 (15.89)	0.75 (6.21)

Release point ROI

 Implicit mentalizing-action	− 5.34 (3.98)	− 1.99 (5.52)

 Implicit either-action	− 6.04 (4.24)	− 3.67 (4.76)

 Explicit mentalizing-non-mentalizinga	− 3.53 (6.81)	− 3.82 (2.70)

	ASD	TD

Head ROI

Implicit mentalizing-action	4.64 (9.68)	2.32 (12.01)

Im	4.32 (8.00)	0.37

plicit either-action		 (11.08)

Explicit mentalizing-non-mentalizinga	0.06 (18.05)	1.91 (13.13)

Poker chip ROI

Implicit mentalizing-action	1.16 (6.15)	− 1.83 (8.76)

Implicit either-action	2.36 (5.58)	2.12 (11.96)

Explicit mentalizing-non-mentalizinga	4.12 (15.89)	0.75 (6.21)

Release point ROI

Implicit mentalizing-action	− 5.34 (3.98)	− 1.99 (5.52)

Implicit either-action	− 6.04 (4.24)	− 3.67 (4.76)

Explicit mentalizing-non-mentalizinga	− 3.53 (6.81)	− 3.82 (2.70)


Name	Genome size (Mbp)	GC Content (%)	Coverage (X)	Scaffolds	N50	Protein coding genes	Reference

AMDSBA1	4.56	52.19	258	155	65,127	4629	This study

AMDSBA2	3.07	52.37	10	409	10,877	3312	This study

AMDSBA3	3.68	55.54	113	129	49,240	3785	This study

AMDSBA4	4.11	51.67	25	179	63,277	4254	This study

AMDSBA5	3.65	49.15	92	161	65,096	3870	This study

S. thermosulfidooxidans AT-1 (DSM 9293)	3.86	49.64	N/D	2	-	3875	IMG JGI

S. thermosulfidooxidans ‘Cutipay’	3.86	49.30	116	35	509,367	3600	Travisany [16]

S. acidophilus NALT (DSM 10332)	3.56	56.75	168	1	-	3626	Anderson [17]

S. acidophilus ‘TPY’	3.55	56.70	26	1	-	3770	Li [2]

Name	Genome size (Mbp)	GC Content (%)	Coverage (X)	Scaffolds	N50	Protein coding genes	Reference

S. thermosulfidooxidans ‘Cutipay’	3.86	49.30	116	35	509,367	3600	Travisany [16]

S. acidophilus NALT (DSM 10332)	3.56	56.75	168	1	-	3626	Anderson [17]

S. acidophilus ‘TPY’	3.55	56.70	26	1	-	3770	Li [2]


STs	Carbapenemase	ESBL

ST11	KPC-2	CTX-14,TEM-1

ST888	NDM-1	CTX-15,TEM-1

ST11	KPC-2	CTX-14,TEM-1

ST11	KPC-2	CTX-15

ST11	KPC-2	CTX-14,TEM-1

ST11	KPC-2	CTX-14

ST20	NDM-1	TEM-1

ST11	KPC-2	CTX-14

ST11	KPC-2	CTX-14,TEM-1

ST11	KPC-2	CTX-14,TEM-1

ST11	KPC-2	CTX-14,TEM-1

ST11	KPC-2	CTX-15

ST11	KPC-2	CTX-14,TEM-1

ST20	NDM-1	CTX-14,TEM-1

ST11	KPC-2	CTX-14,TEM-1

ST20	NDM-1	CTX-14

ST11	KPC-2	CTX-14,TEM-1

ST11	KPC-2	CTX-14,TEM-1

ST11	KPC-2	CTX-14,TEM-1

ST11	KPC-2	CTX-14,TEM-1

ST11	KPC-2	CTX-14,TEM-1

ST11	KPC-2	CTX-14,TEM-1

ST11	KPC-2	–

ST20	NDM-1	CTX-14

ST11	KPC-2	CTX-14,TEM-1

ST11	KPC-2	CTX-14

ST11	KPC-2	CTX-14,TEM-1

ST11	KPC-2	CTX-14,TEM-1

ST20	NDM-1	CTX-14

ST11	KPC-2	CTX-14,TEM-1

ST11	KPC-2	CTX-14,TEM-1

ST20	NDM-1	CTX-14


 	Frequency of complication	In-hospital deaths	Relative risk of in-hospital death

 	N	%	N	%	Adj. RR	95% CI

No complication	18,415	77.5	108	0.6

Complication

Gastrointestinal	263	1.1	18	6.8	3.61	2.32-5.63

Respiratory	636	2.7	44	6.9	2.05	1.30-3.03

Urologic	546	2.3	102	18.7	3.62	2.62-5.00

Infection	449	1.9	18	4.0	2.45	1.47-4.07

Bleeding or acute posthaemorrhage anemia	4,371	18.4	188	4.3	2.11	1.73-2.57

Bleeding or acute posthaemorrhage anemia requiring blood transfusion	3,086	13.0	157	5.1	1.96	1.57-2.44

	Frequency of complication	In-hospital deaths	Relative risk of in-hospital death

	N	%	N	%	Adj. RR	95% CI

No complication	18,415	77.5	108	0.6

Complication

	2	1.1	1	6	3.61	2.32-5.6

	Frequency of complication	In-hospital deaths	Relative risk of in-hospital death

	N	%	N	%	Adj. RR	95% CI

Gastrointestinal	63		8	.8		3

Respiratory	636	2.7	44	6.9	2.05	1.30-3.03

Urologic	546	2.3	102	18.7	3.62	2.62-5.00

Infection	449	1.9	18	4.0	2.45	1.47-4.07

Bleeding or acute posthaemorrhage anemia	4,371	18.4	188	4.3	2.11	1.73-2.57

Bleeding or acute posthaemorrhage anemia requiring blood transfusion	3,086	13.0	157	5.1	1.96	1.57-2.44


Transformable isolateb	Phylogenetic position	Plasmids tested	16S-rRNA gene identityc

Marinobacter sp.	Gammaproteobacteria;	pM1, pM2,	77

	Alteromonadales	pM3

Kocuria rosea	Actinobacteria;	pM2	79

Photobacterium	Gammaproteobacteria;	pM1, pM2,	86

phosphoreum	Vibrionales	pM3

Psychrobacter	Gammaproteobacteria;	pM1, pM2,	96

marincola	Pseudomonadales	pM3

Transformable isolateb	Phylogenetic position	Plasmids tested	16S-rRNA gene identityc

phosphoreum	Vibrionales	pM3

Psychrobacter	Gammaproteobacteria;	pM1, pM2,	96

marincola	Pseudomonadales	pM3


	Cardinal clinical feature

	Ataxia(n = 54)	Tremor(n = 4)	Cognitive deficits(n = 28)	Total(N = 86)

Age (mean ± SD)	67.7 ± 9.1	59.0 ± 8.6	70.0 ± 9.2	68.0 ± 9.3

Age-of-onset (mean ± SD)	59.0 ± 6.8	54.0 ± 1.4	60.5 ± 6.7	59.2 ± 6.7

With additional cardinal features (n)	13	1	4	18

Family history (n)

None	33	3	14	50

Unknown	21	1	14	36


Variable	Mothers	Fathers

	Mean (sd)	Mean (sd)

Age (when index child born)	33.2 (4.7)	34.7 (5.7)

Parental education:

No qualifications	–	1 (0.7%)

GCSE	8 (5.5%)	13 (8.9%)

A levels or equivalent	14 (9.6%)	13 (8.9%)

Diploma or equivalent degree	27 (18.5%)	25 (17.1%)

Degree	46 (31.5%)	51 (34.9%)

Postgraduate	46 (31.5%)	40 (27.4%)

Missing	5 (3.4%)	3 (2.0%)

Parental occupation:

Managerial/professional	81 (55.5%)

Intermediate occupations	39 (26.7%)

Routine/manual	25 (17.1%)

Unemployed	1 (0.7%)

Variable

Age (when index child born)

Parental education:

No qualifications

GCSE

A levels or equivalent

Diploma or equivalent degree

Degree

Postgraduate

Missing

Parental occupation:

Managerial/professional

Intermediate occupations

Routine/manual

Unemployed


Cox proportional hazard ratios	Sites discovered before E.O. [Exp(B)]	Chance of listing (%)a	Sites discovered after E.O. Exp(B)	Chance of listing (%)a

Marginalized populations

 Hispanic (%)	1.002	2	1.005	5

 American Indian (%)	1.003	3	0.923	−77

 Minority (%)	0.998	−2	0.993	−7

 Institutionalized population (%)	1.002	2	0.998	−2

 Elder population (%)	0.999	−1	1.042	42

Wealth and power indicators

 Mean family income ($1,000s)	1.004	4	1.004	4

 Mean value of housing ($1,000s)	0.999	−1	1.006	6

 Owned housing (%)	1.001	1	1.019	19

 Professional careers (%)	1.007	7	0.934	−66

 College degree or higher (%)	1.001	1	0.975	−25

 No high school diploma (%)	1.000	0	1.010	10

 Below the poverty line (%)	0.984	−16	0.969	−31

Gender and family

 Female headed households (%)	1.005	5	1.048	48

 Children < 18 (%)	1.000	0	0.991	−9

Urbanization

 Population density	1.000	0	1.000	0

 Urban	0.998	−2	1.002	2

Site-specific characteristics

 PRPs identified	1.344	134	0.617	62

 Hazardous ranking score	0.977	−23	0.987	−13

Cases

 Listed	1,410		53

 Censored	48		8

 Total	1,458		61

 Missing	21		0

Cox proportional hazard ratios	Sites discovered before E.O. [Exp(B)]	Chance of listing (%)a	Sites discovered after E.O. Exp(B)	Chance of listing (%)a

Below the poverty line (%)	0.984	−16	0.969	−31

Gender and family

Female headed households (%)	1.005	5	1.048	48

Children < 18 (%)	1.000	0	0.991	−9

Urbanization

Population density	1.000	0	1.000	0

Urban	0.998	−2	1.002	2

Site-specific characteristics

PRPs identified	1.344	134	0.617	62

Hazardous ranking score	0.977	−23	0.987	−13

Cases

Listed	1,410		53

Censored	48		8

Total	1,458		61

Missing	21		0


Plant family/Plant sample - Herbarium voucher number	Traditional use	Part used in this study	Potential active compounds characterized	Previously screened activity

APOCYNACEAE/Alstonia boonei De Wild – 43368/HNC	Fever, painful micturition, insomnia, chronic diarrhea, rheumatic pains, anti-venom (snake bites), malaria, diabetes, helminths, arthritis [28, 29].	Leaves, bark	Echitamine, echitamidine, Voacangine, akuammidine, N- α-formylechitamidine, N- α-formyl-12-methoxyechitamidine [29].	Antimalarial, antioxidant, analgesic, anti-inflammatory, antipyretic [30–32].

APOCYNACEAE/Catharanthus roseus L. – 5689/HNC.	Bleeding arresting, diabetes, fever, rheumatism, cancer [20, 33].	Leaves, stem	Vincristine, vinblastine, benzoic acid, p-hydroxybenzoic acid, salicylic acid, 2,3-dihydroxybenzoic acid, 2,5-dihydroxybenzoic acid, 3,4-dihydroxybenzoic acid, 3,5-dihydroxybenzoic acid, gallic acid, vanillic acid, chlorogenic acid, kaemferol trisaccharides, Quercetin trisaccharides, Syringetin glycosides [20, 34].	Wound-healing, antimicrobial, hypoglycemic, antioxidant [18, 20, 33].

ASTERACEAE/Ageratum conyzoïdes Linn. – 19050/SFR-Cam	Purgative, fever, ulcers, wound, mental, infectious diseases, headaches, anti-inflammatory, diarrhea [35, 36].	Whole plant	β-caryophyllene, precocene I, friedelin, Lycopsamine, echinatine,β-sitosterol, stigmasterol, 5-methoxynobiletin, linderoflavone B, eupalestin, sabinene, α and β pinene, β-phellandrene, 1,8-cineole and limonene, ocimene, eugenol [35].	Antimicrobial, anticonvulsant, analgesic, anti-inflammatory, antipyretic, insecticidal, antioxidant, antiplasmodial, cytotoxic [35, 37, 38].

EUPHORBIACEAE/Croton macrostachys Hochst. – 40501/HNC	Malaria, antidiabetic, purgative mastitis, wounds, gastrointestinal Complications [39–41].	Leaves	Neoclerodan-5,10-en-19,6β;20,12-diolide; 3α,19-Dihydroxytrachylobane; 3α,18,19-Trihydroxytrachylobane, lupeol, lupenone, betulinic acid, 28-O-acetylbetulin, betulin, lupeol acetate, zeorin, benzoic acid, methyl gallate, methyl 2,4-dihydroxy-3,6-dimethylbenzoate, lichexanthone, β-sitosterol, and β-sitosterol palmitate, stigmasterol, botulin, crotepoxide [42, 43].	Antimicrobial, antimalarial, cytotoxic [38, 39, 41].

FABACEAE/Cassia obtusifolia L. – 39847/HNC	Laxative, eye infections, diarrhea, urinary tract infections, gingivitis, fever, cough [25].	Whole plant	aloe-emodin, 1-methylaurantio-obtusin-2-O-β-D-glucopyranoside, emodin, 1,2- dihydroxyanthraquinone, obtusin, chrysoobtusin, aurantioobtusin, gluco-obtusifolin, glucoaurantioobtusin, gluco-chryso-obtusin, 1-desmethylaurantio-obtusin, 1-desmethylaurantio-obtusin-2-O-β- D-glucopyranoside, 1-desmethylchryso-obtusin, 1-desmethyl-obtusin, aurantio-obtusin-6-O-β-D-glucopyranoside, alaternin-1-O-β-D-glucopyranoside, chrysoobtusin-2-O-β-D-glucopyranoside physicon-8-O-β-D-glucoside, obtusifolin, O-methyl-chrysophanol, emodin-1-O-β-gentio-bioside, chrysophanol-1-O-β-gentiobioside, physcion-8-O-β-gentiobioside, physcion-8-O-β-glucoside, chrysophanol-1-O-β-D-glucopyranosyl-(13)-β-D-glucopyranosyl-(1 → 6)-β-D-glucopyranoside, chrysophanic acid, physcion, questin, 1,3-dihydroxy-8-methylanthraquinone, chrysophanol- 10,10′-bianthrone, torosachrysone [44].	Antibacterial, antifungal, mosquito larvicidal activity, platelet antiaggregatory, neuroprotective [25, 45–47].

SAPINDACEAE/Paullinia pinnata L. – 10702/SRF-Cam	Malaria, erectile dysfunction [24].	Leaves, stem	Paullinoside A, paullinomides A and B, β-amyrin, 13β,17β-dihydroxy-28-norolean-12-ene, β-sitosterol glucopyranoside, 2-O-methyl-L-chiro-inositol, L-quebrachitol, β-sitosterol, friedelin, daucosterol, aridanin, lotoidoside [24, 48].	Antiparasitic, antimicrobial, cytotoxic [24, 38, 49].

Plant family/Plant sample - Herbarium voucher number	Traditional use	Part used in this study	Potential active compounds characterized	Previously screened activity

FABACEAE/Cassia obtusifolia L. – 39847/HNC	Laxative, eye infections, diarrhea, urinary tract infections, gingivitis, fever, cough [25].	Whole plant	aloe-emodin, 1-methylaurantio-obtusin-2-O-β-D-glucopyranoside, emodin, 1,2- dihydroxyanthraquinone, obtusin, chrysoobtusin, aurantioobtusin, gluco-obtusifolin, glucoaurantioobtusin, gluco-chryso-obtusin, 1-desmethylaurantio-obtusin, 1-desmethylaurantio-obtusin-2-O-β- D-glucopyranoside, 1-desmethylchryso-obtusin, 1-desmethyl-obtusin, aurantio-obtusin-6-O-β-D-glucopyranoside, alaternin-1-O-β-D-glucopyranoside, chrysoobtusin-2-O-β-D-glucopyranoside physicon-8-O-β-D-glucoside, obtusifolin, O-methyl-chrysophanol, emodin-1-O-β-gentio-bioside, chrysophanol-1-O-β-gentiobioside, physcion-8-O-β-gentiobioside, physcion-8-O-β-glucoside, chrysophanol-1-O-β-D-glucopyranosyl-(13)-β-D-glucopyranosyl-(1 → 6)-β-D-glucopyranoside, chrysophanic acid, physcion, questin, 1,3-dihydroxy-8-methylanthraquinone, chrysophanol- 10,10′-bianthrone, torosachrysone [44].	Antibacterial, antifungal, mosquito larvicidal activity, platelet antiaggregatory, neuroprotective [25, 45–47].

SAPINDACEAE/Paullinia pinnata L. – 10702/SRF-Cam	Malaria, erectile dysfunction [24].	Leaves, stem	Paullinoside A, paullinomides A and B, β-amyrin, 13β,17β-dihydroxy-28-norolean-12-ene, β-sitosterol glucopyranoside, 2-O-methyl-L-chiro-inositol, L-quebrachitol, β-sitosterol, friedelin, daucosterol, aridanin, lotoidoside [24, 48].	Antiparasitic, antimicrobial, cytotoxic [24, 38, 49].


Age (Year)	Calibration Model	Total Body Burden (Bq)	Estimated Total Uptake (Bq)	24-h Thyroid Uptake (%)

53	Homogenous	3927 ± 135	4243 ± 146	-

Thyroid and others	3716 ± 128	4015 ± 138	<7.2 ± 1.1

49	Homogenous	2321 ± 165	2508 ± 178	-

Thyroid and others	2320 ± 165	2507 ± 178	<10.7 ± 3.8

35	Homogenous	3918 ± 127	4233 ± 137	-

Thyroid and others	4050 ± 131	4376 ± 142	<16.7 ± 2.7

34	Homogenous	1284 ± 182	1387 ± 197	-

Thyroid and others	1140 ± 162	1232 ± 175	<49.9 ± 11.0

27	Homogenous	2623 ± 195	2834 ± 211	-

Thyroid and others	2454 ± 182	2652 ± 197	<44.1 ± 5.8

Age (Year)	Calibration Model	Total Body Burden (Bq)	Estimated Total Uptake (Bq)

53	Homogenous	3927 ± 135	4243 ± 146

Thyroid and others	3716 ± 128	4015 ± 138

49	Homogenous	2321 ± 165	2508 ± 178

Thyroid and others	2320 ± 165	2507 ± 178

35	Homogenous	3918 ± 127	4233 ± 137

Thyroid and others	4050 ± 131	4376 ± 142

34	Homogenous	1284 ± 182	1387 ± 197

Thyroid and others	1140 ± 162	1232 ± 175

27	Homogenous	2623 ± 195	2834 ± 211

Thyroid and others	2454 ± 182	2652 ± 197


	t3

No/little burden	Moderate burden	(Very) severe burden

t1	No/little burden	22	3	0	25 (48.1 %)

Moderate burden	7	8	3	18 (34.6 %)

(Very) severe burden	0	4	5	9 (17.3 %)

		29 (55.8 %)	15 (28.8 %)	8 (15.4 %)	52 (100 %)

	t3

No/little burden	Moderate burden	(Very) severe burden

t	No/little burden	22	3	0	25 (48.1 %)

M	7	8		18 (3

	t3

No/little burden	Moderate burden	(Very) severe burden

1	oderate burden			3	4.6 %)

(Very) severe burden	0	4	5	9 (17.3 %)

		29 (55.8 %)	15 (28.8 %)	8 (15.4 %)	52 (100 %)


Genotypes	SCA-HU+ patientsN (%)	SCA-HU− patientsN (%)	OR(95% CI)	p value

MPO −463G>A	N = 35 (100%)	N = 66 (100%)


Baseline (Awake)	Baseline (Urethane) 10-20 min	Formalin 1st phase (0-10 min)	Formalin 2nd phase (10-60 min)


Outcome measures	B	3 m	6 m	9 m	12 m	R

Questionnaires

Patient

CCQ	X

MRC dyspnea	X

SGRQ	X	X	X	X	X

McGill QOL	X	X	X	X	X

HADS	X	X	X	X	X

Illness understanding	X	X	X	X	X

Demographic questionnaire	X

Informal caregiver

SPPIC	X	X	X	X	X

HADS	X	X	X	X	X

Illness understanding	X	X	X	X	X

Demographic questionnaire	X

Lung specialist

CRF	X

Medical files

Number of hospitalisations of unexpected hospital admissions for AECOPD	 	 	 	 	 	X

Number of days of unexpected hospital admissions for AECOPD	 	 	 	 	 	X

Number of hospitalisations of unexpected ICU admissions for AECOPD	 	 	 	 	 	X

Number of days of unexpected ICU admissions for AECOPD	 	 	 	 	 	X

Are the choices of ACP documented in the medical file at baseline? (when yes/when no)	 	 	 	 	 	X

Are the choices of ACP documented in the medical file after one year or at time of death? (when yes/when no)	 	 	 	 	 	X

Did the patient die within one year after inclusion? (when yes/when no)	 	 	 	 	 	X

Date of death	 	 	 	 	 	X

Place of death (ICU/hospital/hospice/nursing home/at home)	 	 	 	 	 	X

Is preferred place of death known? (when yes/when no)	 	 	 	 	 	X

Has this wish come true? (when yes/when no)	 	 	 	 	 	X

Primary cause of death (pulmonary insufficiency/other cause)	 	 	 	 	 	X

Secondary cause of death (pulmonary insufficiency/other cause)	 	 	 	 	 	X

Did the patient have an unexpected hospital readmission for AECOPD within 8 weeks? (when yes/when no)	 	 	 	 	 	X

Date of first unexpected hospital readmission for AECOPD.	 	 	 	 	 	X

Outcome measures	R

Questionnaires

Did the patient have an unexpected hospital readmission for AECOPD within 8 weeks? (when yes/when no)	X

Date of first unexpected hospital readmission for AECOPD.	X


 	Botanical name	Family	Common name	Density (ind/hectare) mean ± stdv	Uses

1	Virola surinamensis (Rol.) Warb.	Myristicaceae	Urucurana	97.3 ± 97.1	M, T, O

2	Xylopia brasiliensis Sprengel	Annonaceae	Pindaíba	63.3 ± 60.3	-

3	Carapa guianesenis Aubl.	Meliaceae	Andiroba	46.7 ± 50.3	M, T, O

4	Symphonia globulifera Linn. f.	Clusiaceae	Guanandi/Guananim	43.4 ± 40.4	M, T

5	Mauritia flexuosa L.F.	Arecaceae	Buriti	33.3 ± 32.1	F, S

6	Euterpe oleraceae Mart.	Arecaceae	Juçara/Açai	33.3 ± 43.6	F, H

7	Richeria dressleri G.L. Webster	Phyllanthaceae	Jaca-da-baixa	30.0 ± 43.6	-

8	Anacardium sp.	Anacardiaceae	Caju-da-baixa	26.7 ± 46.2	F

9	n.i.	n.i.	Casca-grossa	20.0 ± 34.6	-

10	Attalea maripa (Aubl.) Mart	Arecaceae	Inajá	16.7 ± 15.3	F, H, O

11	Tapirira guianensis Aubl.	Anacardiaceae	Pau-pombo	16.7 ± 15.3	-

12	Annona sp	Annonaceae	Araticum-da-baixa	13.3 ± 5.8	F

	Botanical name

1	Virola surinamensis (Rol.) Warb.

2	Xylopia brasiliensis Sprengel

3	Carapa guianesenis Aubl.

4	Symphonia globulifera Linn. f.

5	Mauritia flexuosa L.F.

6	Euterpe oleraceae Mart.

7	Richeria dressleri G.L. Webster

8	Anacardium sp.

9	n.i.

10	Attalea maripa (Aubl.) Mart

11	Tapirira guianensis Aubl.

12	Annona sp

Family	Common name	Density (ind/hectare) mean ± stdv	Uses

Myristicaceae	Urucurana	97.3 ± 97.1	M, T, O

Annonaceae	Pindaíba	63.3 ± 60.3	-

Meliaceae	Andiroba	46.7 ± 50.3	M, T, O

Clusiaceae	Guanandi/Guananim	43.4 ± 40.4	M, T

Arecaceae	Buriti	33.3 ± 32.1	F, S

Arecaceae	Juçara/Açai	33.3 ± 43.6	F, H

Phyllanthaceae	Jaca-da-baixa	30.0 ± 43.6	-

Anacardiaceae	Caju-da-baixa	26.7 ± 46.2	F

n.i.	Casca-grossa	20.0 ± 34.6	-

Arecaceae	Inajá	16.7 ± 15.3	F, H, O

Anacardiaceae	Pau-pombo	16.7 ± 15.3	-

Annonaceae	Araticum-da-baixa	13.3 ± 5.8	F